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CHAPTER 1 
INTRODUCTION 
1.1 Fetal vulnerability to drugs and chemicals 
1 
In our daily lives we are exposed to a great variety of chemicals. In 1980 an estimated 
55,000 chemicals were in use, and approximately 650 new chemicals enter the market-
place every year (Schardein, 1985a). Many of these chemicals are synthesized in 
minute quantities for experimental purposes, but every year new chemicals are 
produced that achieve wide distribution, whether as therapeutic drugs, new plastics, 
or herbicides. 
Many of these substances carry hidden hazards that become apparent after many 
years of use. In the industrial nations particularly, there have been a number of public 
campaigns and legal battles over substances that have been claimed to be harmful to 
people and to the environment. Organic mercury, DDT, and dioxin are examples of 
chemicals that have had restrictions placed on their use. Substances that are made 
available for therapeutic use are more carefully controlled, but there are historical 
examples of medicines that were thought to be safe and yet have proved to be toxic in 
unexpected ways. 
Since the early 1960's it has been mandatory to test new drugs for possible ill effects 
on the fetus as well as the adult. Adult animal testing alone is no longer adequate 
because the developing organism has numerous molecular and cellular events that 
are unique to it. Consequently, a substance that has been demonstrated to be 
completely non-toxic to the mother may nevertheless lead to injury to the fetus. 
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Any agent that damages the fetus is called a teratogen, and the study of injury to the 
fetus is called teratology. These words stem from the Greek root "teras", meaning 
monstrosity. However, birth defects need not be gross. Schardein (1985b) defines a 
teratogen as "an agent that induces structural malformations, metabolic or 
physiological dysfunction, or psychological or behavioural alterations or deficits in the 
offspring, either at birth or in a defined postnatal period". 
1.2 Thalidomide : The Spur for Experimental Teratology 
Thalidomide ingestion by pregnant women in the late 1950's and early 1960's resulted 
in thousands of malformed infants, the majority with limb malformations, a few with 
more severe generalized malformations. The manufacturer of the drug, Chemie 
Grunenthal, had declared thalidomide totally free of toxicity, and had explicitly stated in 
an advertisement, that thalidomide "does not damage either mother or child". {Teft 
and Munro, 1976). 
These claims were based on what would today be regarded as very inadequate 
animal tests. Although general toxicity studies were done using mice, rats, guinea 
pigs and rabbits, no teratogenicity testing was done before thalidomide was released 
to the marketplace (Schardein, 1985c). However, it should be remembered that 
Chemie Grunenthal had not in fact broken any laws. As Wilson (1979) pointed out, in 
the 1950's there were few official guidelines and no legal requirements regarding 
teratogenicity testing. He claimed that "even if appropriate animal tests had been run 
and the results been available prior to 1960, it is questionable whether they would 
have been applied in such a manner as to have avoided the thalidomide or some other 
occurrence". The reason for this is because "neither the concepts nor the technology 
of prior animal testing had evolved to the point where they could have been 
intelligently applied" to the estimation of teratogenic risk (Wilson, 1979). 
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Today, the "FDA Guidelines of 1966" have, with some modifications, been adopted by 
most of the regulatory agencies in the West. The legislation instituted by the FDA 
requires that no drug for human consumption, which may be administered to pregnant 
women, will be released for sale without first having been tested in at least two rodents 
and one other of the dog, rabbit, or cat (Shepard, 1979). 
Animal studies give no guarantee that a drug which fulfills the legal requirements of 
animal testing for teratogenicity, will be innocuous to the human fetus. For instance, 
thalidomide is not a potent teratogen in the commonly used laboratory animals, and 
limb defects on the same pattern as those found in humans, have been observed only 
in a few breeds of rabbits and in primates. It is therefore not inconceivable that the 
extreme toxicity of thalidomide to the human fetus would not have been appreciated 
even if the FDA guidelines had been applied prior to its release. None of the known 
human teratogens has been identified using animal studies, although animal studies 
have been useful in elucidating the principles and mechanisms of teratogenesis 
(Chernoff and Lyons Jones, 1981). 
The mechanism of thalidomide injury to the unborn remains as much of a mystery now 
as it was 25 years ago. A number of mechanisms of action have been proposed, but 
no hypotheses has yet been proved. Schardein (1985d) listed some of the possible 
mechanisms: folic acid antagonism, acylation, intercalation with nucleic acid, 
interference with glutamic acid metabolism, vitamin antagonism, chelation of essential 
bivalent cations, deranged nucleic acid and protein synthesis, immunosuppression, 
and formation of an arene oxide metabolite. The pathogenesis of thalidomide-
induced malformations appears to be just as obscure as its mechanism of action. 
Mccredie and Macbride (1973) proposed that the embryo suffers a peripheral 
neuropathy during thalidomide teratogenesis, and suggested that if this occurs at the 
stage when the spinal nerves are developing, then the result would be incomplete or 
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absent limb bones. Since then it has been shown that in fact skeletal morphology is 
independent of innervation (Strecker and Stephens, 1983). 
The determination of the mechanism of action, and pathogenesis, of a suspected 
teratogen, may be seen as an important adjunct to the process of predictive 
teratogenicity testing using animals. The reason is that once the mechanism of action 
of a teratogen is known, then it may be possible to predict, on the basis of structural 
similarity, related biochemical action, or effect, which new drugs (and metabolites of 
these drugs) may also be teratogenic. In addition, once the pathogenesis is known, it 
may become more evident which of the developmental processes are critically 
sensitive to disruption by xenobiotics. 
1.3 Teratogenic Susceptibility and the Stage of Development 
The fetus is susceptible to drug injury in different ways during intrauterine life. During 
the preimplantation and presomite periods, drug ingestion by the mother may lead to 
death and abortion of the embryo. Exposure to teratogens during the critical periods 
of organogenesis will make normal patterns of growth vulnerable to disruption. Once 
fetal organogenesis is complete, there is less likelihood that exposure to a teratogen is 
likely to have a teratogenic outcome. 
In experimental animals comprehensive information is available on the different stages 
of organogenesis. For instance, in the rat the period of active embryological 
differentiation occurs between day 8 and day 16 (Wilson, 1973). A teratogen must 
normally be administered to the pregnant animal during this period for specific 
structural malformations to occur in the offspring. It is generally held that the organ 
that is the most actively differentiating at the time of the exposure to the teratogen will 
be the most affected. For example, the eye and the heart of the rat achieve maximum 
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growth on day 9, and we therefore expect both organs to be the most vulnerable to 
injury at this time. The brain, which achieves optimal development about a day later, 
will also be vulnerable, whereas the urogenital system, which develops late in 
organogenesis, is likely to be unaffected. 
Thalidomide produced malformations in children when taken on days 20-36 following 
conception, which is well within the period of most active organogenesis (which ends 
at about 12-14 weeks). Abnormal ears occured when thalidomide was taken on days 
20-24, whereas phocomelia of the limbs was induced on days 27 to 33. Ingestion of 
the drug between day 27 and day 30 was associated most often with defective arms, 
whereas ingestion from day 30 to day 33 caused more leg deformities with less 
involvement of the arms (Shepard, 1979). These findings correlate with the 
appearance of the lower limb buds in the human embryo at about day 30. 
It may be possible to establish a casual link between drug ingestion and birth defects 
by showing that maternal drug ingestion occurred at a specified time during 
pregnancy. For instance, Rivas and colleagues (1984) have made such an association 
in a single case report of a craniofacial cleft in a child. In the human the development 
of the frontonasal prominence occurs at the end of the sixth week. Rivas and 
colleagues were able to establish that the mother had taken a large single dose of 
diazepam on day 43 of gestation. On the strength of this temporal concordance, and 
despite epidemiological evidence to the contrary (Rosenberg et al. , 1983), the authors 
proposed an aetiological relationship between diazepam ingestion by the mother 
concerned and the oral cleft in the child. 
1.4 Mother and Fetus: Biological Distinctions 
For some time it was believed that the placenta was a shield for the fetus, and that any 
toxic effects due to drug ingestion were experienced by the mother alone. This matter 
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has been completely re-evalued. "It is clearly evident that there really is no placental 
barrier per se: almost all chemicals given the pregnant animal (or woman) reach the 
fetus in significant concentrations soon after administration" (Schardein, 1985e). In 
fact, the placenta and fetus have some drug metabolizing capacity and may even 
generate toxic intermediates. 
The way in which mother and fetus respond to drugs may differ markedly. 
Thalidomide, at dosages that achieve therapeutic efficacy, is the best example of a 
substance that is relatively non-toxic in adults, but is a powerful teratogen. Likewise, 
inorganic cadmium may cause widespread morphological and neurological damage in 
immature animals. Inorganic cadmium does not enter the mature central nervous 
system, but does enter the central nervous system of developing animals with relative 
ease. (Newland et al., 1986). In the brain of the chicken embryo, naloxone does not 
reverse the inhibition of adenylate cyclase by morphine between days 6 to 8 
(Sakellaridas and Vernadakis, 1986), indicating that there is a transitory form of the 
enzyme in the chick which is not found in the adult. 
That chemical substances should often have different effects on the mother and the 
fetus is to be expected. While mother and fetus have close genetic kinship, the 
patterns of gene expression are under independent control. Adult and fetal cellular 
phenotypes may differ profoundly, with many fetal tissues made up partly of 
undifferentiated cells. The result is that the fetus will produce proteins that are 
qualitatively and quantitatively different from those of the adult organism. 
The biosynthetic enzymes are highly active during development. In the central 
nervous system the activities of enzymes of purine biosynthesis are apparently related 
to the level of nucleic acid synthesis. Dominguiez and Ordonez (1982) found that early 
in the development of the rat central nervous system, the levels of two folate-
dependent enzymes of de novo purine biosynthesis are more than nine times above 
adult levels. Ornithine decarboxylase is another enzyme that is developmentally 
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regulated. Slotkin and co-workers (1984) have shown that this enzyme is present at 
high levels during phases of differentiation and cell growth as well as replication , and 
as cells mature or growth ceases the levels decline. 
Qualitative differences in protein biosynthesis are evident at the level of tissue and 
organ. Fetal and adult blood proteins differ in the type of haemoglobin that is 
expressed. Kastern and colleagues (1986) report that in the human fetus the level of 
alpha1-microglobulin peaks at 15-17 weeks and then rapidly
 decreases until birth. 
There are differences in myocardial function among fetal, newborn and adult animals. 
The immature heart operates near the plateau of the cardiac function curve, which 
Mahoney and Jones (1986) claim is due to there being more junctional sarcoplasmic 
reticulum in fetal hearts. 
These fetal cellular phenotypes must mature in a scheduled way. If any step in this 
process is inhibited or delayed then subsequent steps may be delayed or will not take 
place at all. Fetal development is sequential and every stage is under temporal 
constraint. The fetus differs not only from the adult because it has different proteins 
and tissues, but also because it is vulnerable in a temporal sense. The mother is not 
vulnerable in the same way and drug injury that is not too severe may be overcome by 
synthesizing cellular components anew or by regenerating damaged tissue. Although 
we may expect the fetus to have some capacity for repair, any disruption of the 
schedule of its developmental programme is likely to result in structural and functional 
shortcomings at birth, which we then refer to as teratogenic damage. 
1.5 Development of the Brain. Molecular and Cellular Aspects 
1.5.1 Phase of Maximal Growth 
In the mouse embryo the central nervous system is the first organ to begin 
development. At 71 / 2 days, when the neuronal groove, neural plate and head process 
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stages have been completed, the primary parts of the brain can already be identified 
(Rugh, 1968). By day 14 the mouse brain is typically that of a mammal. The period 
from day 71 / 2 to day 14 is therefore one of rap
id and extensive organogenesis. It is 
during this "growth spurt" that developmental processes in the brain are particularly 
sensitive to disruption. 
As may be expected the rate of protein synthesis during the "growth spurt" is high. 
Gilbert and Johnson (1974), using cell suspensions derived from mouse brain, found 
that protein synthesis activity was very high on the 13th gestational day, and that 
between the 13th day of gestation and adulthood there was a 25-30 fold decrease in 
the rate of protein synthesis. In a later study done on intact fetal rat brain, Johnson 
(1985) established that the high rate of protein synthesis is accompanied by a lower 
rate of degradation, as compared with the neonatal rat brain. Qualitative protein 
changes are likewise extensive during fetal development, and the brain protein 
complement constantly changes as the brain matures (Hoshida and Takahashi, 1980). 
During the "growth spurt" the fetal brain may be particularly vulnerable to drugs that 
interact with any of the numerous components of the complex machinery of protein 
biosynthesis. For example, xenobiotics may influence protein biosynthesis by 
intercalating with DNA bases, or with RNA; by binding to the ribosome; by disrupting 
translation or post-translational modifications. Disruption of genes that regulate the 
expression of other genes is likely to have profound effects. An enzyme inhibitor may 
lead to the loss of that protein only, whereas drugs that destroy the cell membrane 
may lead to the deletion of a whole population of cells. Teratogens therefore have a 
variety of potential targets, and some of them may simultaneously disrupt a number of 
different cellular components. 
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1.5.2 Neuronal Outgrowth 
The great complexity of the brain arises not only from its cellular diversity, but also 
from the extent of the interconnections between neurones. There are an estimated 
1 O 11 neurones in the human brain, each of which makes 1 o4 connections with each 
other neurone (Black, 1986). These connections are not random but are uniquely 
specified by genetic and epigenetic factors. Despite this complexity however, detailed 
knowledge of brain biology has been obtained from the study of the simple and 
accessible segmented nervous systems of lower animals. 
Neurones differentiate from neuronal precursor cells as a family of closely related but 
not identical cells. As it differentiates, each neurone undergoes unique interactions 
with other neurones or with neuroepithelium. These interactions involve a series of 
sequential cell recognition events between each neurone and its substrate. If a cell 
that forms part of the substrate is experimentally ablated, then the neurone will not 
show affinity for any other cell (Thomas et al., 1984). The distinctive neuronal 
morphology is therefore generated by the way in which the developing neurone 
interacts with neighbouring cells. 
Cell recognition during neuronal outgrowth requires the temporal and spatial 
expression of many different cell-surface molecules. One of these membrane proteins 
is the neuronal cell adhesion molecule (N-CAM) (Rutishauser, 1984). N-CAM is 
transiently expressed at sites that provide selective adhesion for neurones. Changes 
in the carbohydrate content of N-CAM can produce a hierarchy of binding affinities 
(Sunshine et al., 1987), and it is this differential affinity among neurones that 
determines their unique morphology (Edelman 1985; Edelman, 1986). The process of 
neuronal differentiation is therefore a fine interplay between intrinsic cellular programs 
and signals from the extracellular environment. 
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Immunological techniques have confirmed the heterogeneity of neurones in the mouse 
central nervous system, and cell surface markers have been described to distinguish 
between subclasses of neurones (Schnitzer et al. , 1984). Developmentally distinct 
classes of oligodendrocytes have also been distinguished, and astrocytes and 
subclasses of astrocytes have been recognised by several markers (Schnitzer et al. , 
1984). In view of the large variety of cell types, and the complexity of their 
interconnections, it is to be expected that the brain has a large number of sites where 
potentially harmful drugs may act. The developing brain experiences complex spatial 
and temporal biological events. In the fetal brain we may therefore expect a wide 
spectrum of teratogenic manifestations, ranging from gross structural damage to mild 
behavioural maladaptations. 
1.5.3 Postnatal development 
Of all the organs the brain takes the longest to mature. Brain development in many 
species is not completed until well after birth. In altricial species, especially, 
morphogenesis extends well into the post-natal period (Brunjes, 1983). In the mouse, 
as well as the rat, axonal and dendritic growth, synaptogenesis, gliogenesis, and 
myelination takes place within the first weeks after birth (Knaus et al., 1986; Burgoyne 
et al. , 1981 ) . 
There are numerous examples of postnatal maturation of the brain. In the 
hypothalamic-pituitary of the rat oestradiol receptors reach maximum concentration on 
the 15th day after birth (Maclusky et al., 1979). Likewise, a neuronal cell-surface 
sialidase isolated from the rat attains maximum expression on the 20th day after birth 
(Moran et al., 1986). Desialylation is at a maximum during the time of extensive 
synaptogenesis, and the amount of sialic acid is thought to regulate cellular plasticity. 
Oohira and co-workers (1986) report that the glycosaminoglycan content of the rat 
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brain reaches a plateau by 1 O days after birth. Glycosaminoglycans constitute the 
extracellular matrices of various tissues, and changing levels of the different 
glycosaminoglycans during the process of organ development are thought to have an 
important role in morphogenesis. 
During the development of the fetal brain into a mature organ, the various cells of the 
brain undergo transitions from proliferating, undifferentiated precursor cells to non-
proliferating, terminally differentiated cells. This process extends well into the 
postnatal period and is reflected in changes in protein composition. An analysis by 
Burgoyne and co-workers (1981) of 59 polypeptides from fractions of rat cerebral 
cortex revealed that three polypeptides increased in amount during postnatal 
development. Yoshida and Takahashi (1980) did a detailed electrophoretic study of 
the proteins of rat cerebral mantle, cerebellum, and brain stem. At every 
developmental stage the electrophoretic profile was different, although in fetal animals 
the three regions were very similar in composition. During the postnatal period there 
was a remarkable increase in the number of polypeptides in all three regions, 
suggesting that proteins become more heterogeneous during postnatal development. 
Non-histone proteins and histones from rat neuronal and glial cells undergo increased 
acetylation and phosphorylation up to 30 days after birth (Serra et al., 1986 ) . 
Heizmann and co-workers (1982) demonstrated that many single-stranded DNA-
binding proteins undergo conspicuous developmental fluctuations, especially in the 
perinatal period and the first postnatal week. 
The extensive and protracted postnatal modulations of gene expression may be 
crucial to the successful maturation of the organism. If this is so then the rodent brain 
will be vulnerable to teratogens for an extended period of time. Schardein (1985a), in 
his definition of a teratogen, has included the postnatal period as a time during which 
developmental processes may be disrupted. Conceptually, injury to the brain in the 
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postnatal period is the same as prenatal injury, if the outcome is structural or functional 
deficits in adulthood. 
1.6 Experimental Approaches to Drug Injury to the Fetal Brain 
1.6.1 Macroscopic Examination 
Injury to the fetus may be assessed in experimental animals by noting the number of 
resorptions and intrauterine deaths, as well as litter size, birth weight, sex ratios, 
malformations to limbs and organs, and intrauterine position (Cornwall et al., 1984). 
Fetal brain weight was used by Patsalos and Wiggins (1982) to assign relative 
teratogenic risk to a number of potential central nervous system teratogens. Likewise, 
exencephaly, enlarged cerebral ventricles and open eyes in experimental animals 
have been used to assess the degree of central nervous system teratogenicity of a 
number of drugs (Sullivan and McElhatton, 1977). Johnson and colleagues (1985) 
found that procarbazine administration to pregnant rats leads to microencephaly in the 
offspring. Depending on the dosage and the day of administration, the various 
regions of the brain were affected differently. The neocortex suffered the greatest size 
reduction; the hippocampus, cerebellum, and the encephalon - midbrain were also 
reduced in size, while the corpus striatum and pons-medulla were spared. Of course, 
a teratogen may not result in discernible physical damage to the fetus, but may 
nevertheless cause behavioural deficits after birth (Voorhees et al., 1979). 
1.6.2 Ultrathin Sectioning of the Brain 
Histological· staining in conjunction with light microscopy has been used on ultrathin 
sections of fetal brain, in order to detect any lesions that were possibly caused by 
drugs that had been administered to the mother. Bergman and co-workers (1980) 
obtained ultrathin sections from fetal mouse brain, and demonstrated that maternal 
exposure to phenobarbitone resulted in a reduction in the number of Purkinje and 
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pyramidal cells; Yanai and Bergman (1981) demonstrated the same effect by using 
granule cells. In neonatal mice, phenobarbitone exposure has been found to reduce 
the number of dendritic spines of Purkinje cells (Yanai and Iser, 1981). Hannah and 
co-workers (1982), using sections of the rat cerebellum, have demonstrated that 
chlorpromazine exposure also leads to a reduction in Purkinje cell number in the 
developing brain. 
Transmission electron microscopy may be used to study intracellular changes in 
developing brain. For example, by studying ultrathin brain sections from mice, 
Fishman and co-workers (1983) found that phenobarbitone exposure leads to 
degeneration of mitochondria and also to the disintegration of the myelin sheath. 
1.6.3 Tissue Culture 
Brain slices may be placed in a nutrient medium and the cells monitored in the living 
state by light microscopy. Drugs at defined concentrations may be added directly to 
the medium. Alternatively, explants of sections of the brain may be used; they can -be 
kept alive in a nutrient medium for as long as 28 days. For instance, Blank and 
colleagues (1982) were able to show that neonatal mouse cerebellar cultures that 
were exposed to phenytoin underwent cortical degeneration, while explants derived 
from mature animals were more resistant to phenytoin. 
Tissue culture more commonly involves maintaining cells in their dissociated state. 
Different brain cell types may be obtained in a virtually pure form, and drug effects on 
these cultures may be determined. Bergey and coworkers (1980) used fetal mouse 
spinal cord neurones, and found that phenobarbital produced dosage-dependent 
decreases in neurone counts. A similar effect was found with pentobarbitone on nerve 
and glial cells obtained from chick embryos (Roth-Schechter and Mandel, 1976). 
Phenytoin, too, has a cytotoxic effect on neurones in culture, as Swaiman and 
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colleagues (1982) were able to show, using cells obtained from the cerebral cortex of 
fetal mice. Pure cultures of dissociated cells also lend themselves to detailed cellular 
and biochemical analysis, although it appears that this avenue of teratological 
research has been relatively neglected (see 1.6.4). 
1.6.4 Molecular studies 
As yet very little is known about the molecular events that accompany drug injury to 
the fetus. Even less is known about the molecular teratology of the brain, and it is 
probably because of its complexity that this organ has been the subject of so few 
biochemical investigations. The few molecular studies that have been done merely 
emphasise how little is known about those critical biochemical events that are 
perturbed by teratogens. 
This state of affairs is partly due to the limitations of a holistic approach, where the 
starting material is often extremely complex, and from which a promising line of 
biochemical attack must be taken. The alternative is a reductionistic approach, which 
involved the dismantling of cellular components of interest and then reassembling 
them in a highly simplified but still functional system. Such an approach gives the 
investigator more versatility in formulating and proving hypotheses; unfortunately, until 
more is known about which the cellular components of interest are, the holistic 
approach will continue to be used. 
Bergey and coworkers (1980) investigated the effect of phenobarbitone on the enzyme 
choline acetyltransferase. Cell cultures of fetal rat spinal cord were used, and this 
enzymatic work was part of a three-pronged approach that included cellular and 
histological observations. Although phenobarbitone was found to produce dose-
dependent decreases in the enzyme, this finding does not tell us more about 
phenobarbitone as a teratogen, beyond the fact that it is potentially harmful. Any 
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attempt to determine the underlying molecular processes will require extensive and 
specific knowledge of the cellular physiology and biochemistry of the particular cell-
type. It is reasonable to suppose that the more restricted the experimental context is, 
the easier it will be to establish a direct link between macroscopic damage and 
molecular events, and the easier it will be to assess the potential usefulness of a 
screening procedure. 
The use of a biosynthetic pathway to detect drugs that are harmful to the fetal brain 
has been adopted by Slotkin and coworkers (1985). They chose the enzyme ornithine 
decarboxylase, which catalyses the initial step in the synthesis of polyamines; 
polyamines in turn play a regulatory role in macromolecular synthesis during 
replication, differentiation and growth. It is known that drugs, hormones and 
environmental conditions may perturb the ornithine decarboxylase/polyamine system, 
and Slotkin and his co-workers postulated that such a perturbation may account for 
the widespread disruption of fetal tissue that some teratogens cause. They proposed 
therefore that ornithine decarboxylase levels or activities may be used as a 
biochemical marker for teratogenic events. 
Such an approach does not solve the difficulty of distinguishing between primary and 
secondary events. Since cellular biosynthetic pathways are closely linked, it is 
probable that some of the widespread perturbations attributed to ornithine 
decarboxylase suppression or inhibition are partly the result of the disruption of a host 
of other pathways. For this reason the use of ornithine decarboxylase as a 
biochemical marker may be of limited value both in screening for new drugs of 
teratogenic potential and for the determination of the mechanism of action of a known 
teratogen. 
Another difficulty in the molecular approach is to distinguish toxic from teratogenic 
mechanisms. For instance, Garrett and Tabakoff (1986) found that rats that had been 
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exposed to phenobarbitone in utero had 17% fewer benzodiazepine receptors at 
birth, compared to controls. However, the chronic administration of phenobarbitone 
to adult mice also reduces the number of benzodiazepine receptors in the brain. 
Moreover, in the in utero experiment, if the drug exposure was stopped at birth, then 
the benzodiazepine receptor number returned to normal. It may well be that every 
xenobiotic has widespread effects within cells, with some of these effects being toxic, 
and that only at a specific dosage and at a specific point in time will a teratogen disrupt 
a critically susceptible biochemical pathway in such a way as to produce a 
teratogenic outcome at birth. 
1. 7 The Experimental Mouse 
Every human teratogen was uncovered either through case reports or epidemiological 
research, and there are limitations to the predictive value of animal experimentation. A 
short program of animal experimentation is unlikely to direct suspicion to a drug that 
may only after many years of human use be discovered to have subtle teratogenic 
manifestations. Part of the difficulty of using animals to screen potential human 
teratogens is that "almost all the putative teratogens in the human have teratogenic 
activity at fractional dosages compared with those demonstrated in the laboratory in 
various species" (Schardein, 1985f). 
Nevertheless, animals generally are far more susceptible to other human teratogens 
than they are to thalidomide, and animal testing must be performed satisfactorily 
before a new drug may be registered. In terms of their close phylogenic relationship to 
humans, the primates should be the most suitable animals to use for testing; 
unfortunately they are expensive to use and their birth rate is low. Rodents are the 
most extensively used animals and Tuchman-Duplessis (1972) claimed that no 
chemical exists that is teratogenic in the human that has not produced malformations 
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in rodents. There is the ever-present danger that negative results in rodents may be 
used to predict that an agent will lack teratogenic effect in humans; for this reason a 
non-rodent animal must also be used in teratogenicity testing of a new drug. 
In the present study mice were used because of the many advantages they have over 
other experimental animals. They are readily available and easy to feed, raise, mate 
and handle. Because they are small, they are inexpensive, but nevertheless are big 
enough to manipulate without difficulty. The duration of pregnancy is short, fertility 
rate are high, and litters are large. Although mice show good resistance to the toxic 
effects of most drugs, they are nevertheless fairly susceptible to teratogens. A 
drawback is that mice have a fairly high spontaneous malformation rate (0.5% in Swiss 
albino colony) which means that fairly large control groups are needed (Tuchman-
Duplessis, 1972). Various in-bred strains are available, with interstrain differences in 
susceptibility to teratogens (Hansen and Hodes, 1983). Because the mouse has been 
extensively used in experimental teratology and as a general laboratory animal, there 
is a large body of accumulated knowledge on this animal. 
1.8 Two-dimensional Gel Electrophoresis 
Two-dimensional gel electrophoresis makes it possible to examine a large number of 
different protein molecules simultaneously. The technique is regularly used to give a 
display of the protein complement of a particular tissue, and is ideally suited to the 
examination of the effects that experimental manipulations may have on protein 
expression. A solubilized tissue sample is subjected first to isoelectric focussing and 
then to sodium dodecyl sulphate polyacrylamide gel electrophoresis. In the first 
dimension proteins are separated by charge and in the second dimension by mass. 
Within these parameters a thousand or more proteins may be resolved from a complex 
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mixture. Test and control gels may be compared for qualitative and quantitative 
changes to these proteins. 
Two-dimensional gel electrophoresis has been used to visualise the modulation of 
protein synthesis by xenobiotics. In a study using regenerating mouse liver, 
isoproterenol and phenobarbitone were shown to change nuclear protein 
concentration, including some of the histones (Pipkin et al., 1985). In toxicological 
studies, two-dimensional gel electrophoresis has been used on various tissues. The 
widely used organic solvent dimethylformamide was used to induce minor protein 
changes in the serum of rats when the solvent was injected intraperitoneally; two 
proteins, lgG and x1-acid glycoprotein were tentatively iden
tified, but no suggestion 
was offered regarding the mechanism of this effect (Marshall et al., 1985). When 
Aroclor 1254, a mixture of chlorinated biphenyls, was injected intraperitoneally into 
mice, 31 protein changes were found in a liver extract following two-dimensional gel 
electrophoresis (Anderson et al., 1986). One of the proteins that underwent a change 
was cytochrome b5, an electron transport protein, and th
e authors speculated that 
each of the protein changes may play an important part in the mechanism of toxicity. 
The effect of drugs on brain tissue has been the subject of few studies using two-
dimensional gel electrophoresis. When administered chronically, 
desmethylimipramine resulted in a reduction in the concentration of two proteins in the 
parietal cortex and the hippocampus of rats, and also lead to the increase in 
concentration of a single protein (Heydorn et al. , 1984). In contrast, chronic treatment 
with reserpine produced effects on these three proteins in the hippocampus which 
were quantitatively opposite to those obtained after chronic desmethylimipramine 
administration. Since both agents affect noradrenergic reactivity, the authors 
postulated that one of these proteins is tyrosine hydroxylase, an enzyme involved in 
noradrenergic neurotransmission. 
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Although there have been two-dimensional electrophoretic studies on fetal brain tissue 
(for instance, Yoshida and Takahashi, 1980), the emphasis in most of this work has 
been on developmental changes in protein expression, and not on the effects that 
drugs have on fetal brain protein complement. Klose and co-workers (1977) did an 
early study using two-dimensional gel electrophoresis to determine the effects of 
various teratogens on whole embryos. No protein changes were found and that line 
of research was not continued. 
In this study two-dimensional gel electrophoresis is extensively used, in the belief that 
the usefulness of this technique to experimental teratology has not been fully 
evaluated. It is reasonable to suppose that a central nervous system teratogen 
administered during critical periods of susceptibility will led to perturbations of orderly 
brain development, and that these perturbations will be reflected as changes to the 
protein complement. The total brain protein complement of mice that have been 
exposed to drugs in utero will therefore be analysed, in the hope that any inductions 
or deletions of proteins as a result of drug exposure may provide a clue to the 
molecular events underlying drug injury to the fetus. 
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2.1 Manipulation of experimental animals 
2.1.1 Choice of Mouse 
c3H mice were used to evaluate the effects of selected
 drugs on proteins of the fetal 
brain. The c3H strain (full designation c3H/HeAfHg/lCR) is known to be moderately
 
susceptible to teratogens (Hansen and Hodes, 1983). Other advantages wer
e 
availability and the fact that details of breeding and drug administration have already 
been established (Pillans et al., 1988). 
It was essential to select an inbred strain, because individual animals from such strains 
have low genetic variability. Among inbred animals the range of responses to drug 
injury between individuals is kept to the minimum (Kalter and Warkany, 1961) and this 
makes it easier to differentiate between test and control in the response to drug injury. 
Low genetic variability is achieved by repeated matings of genetically closely related 
individuals. Usually an inbred strain is accomplished by more than 20 generations of 
brother-sister matings. 
A feature of the c3H strain that was potentially disadvantageous was a high 
spontaneous abnormality rate (Heinecke, 1972). This detriment was overcome by 
using large numbers of control animals. 
2.1.2 Conditions of Housing 
Animals were kept in an environment that was carefully regulated to be optimal for their 
maintenance and breeding. This included a light-dark cycle of 12 hours, air 
temperature at a constant 21°c, constant humidity, and 12 to 15 air changes per hour. 
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Animals were housed in plastic cages that were cleaned twice a week and autoclaved 
approximately every two weeks. Fresh bedding (consisting of wood chips) was 
sterilized before being placed in cages. Food and water was allowed ad libitum. The 
food consisted of 13 mm mice cubes. At one stage food was autoclaved after 
delivery, but this practice was discontinued when it was noticed that fertility rates had 
drastically declined; low fertility rates possibly resulted from the destruction by heat of 
important nutrients in the feed. 
Females were housed communally in large cages, while males were kept individually 
in small cages of approximately 450 cm
2 floor area. 
2.1.3 Mating Protocol 
Animals were supplied from breeding stocks once they had achieved reproductive 
maturity (6-8 weeks). Only virgin females were used for matings. Males were regularly 
weighed to ensure that they fell within a 24,5 - 27,5 g weight optimum. Stocks were 
renewed every 8 weeks. 
Animals were mated one male to one female. The females were placed in the cages 
with the males at 17h00, and left there overnight. Mice are nocturnal breeders, and 
oestrus begins in 75% of mice 4-6 hours after dark (Hafez, 1970). 
In the morning females were separated from the males and inspected for the presence 
of a copulation plug. The presence of a plug is a reliable indicator that mating had 
occurred. Midnight on the night of mating was taken as the time of conception and 
designated Day 0. 
The pregnancy rate normally fell in the range 15-20%, but sometimes increased or 
decreased markedly, for reasons unknown (apart from low pregnancy rates attributed 
to feed that had been autoclaved). The mating success of each male was recorded. 
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Males with a low mating frequency, or males that were overweight, were not used for 
mating. 
2.1.4 Drug Administration 
Drugs were administered to pregnant females on day s 1 / 2 or day 9
1 / 2 post 
conception, which coincides with the period of rapid fetal brain development 
(Nishimura and Shiota, 1977). It is believed that the fetal brain is most vulnerable to 
central nervous system teratogens during the period of active organogenesis (see 
Section 1.3). 
Drugs were administered by means of gastric intubation. Animals were carefully 
immobilized to prevent them from wriggling, and a curved needle with a bulbous tip 
was carefully introduced into the stomach. At no stage was the the intubation process 
hastened or forced. Great care was taken to avoid causing the animal any pain, and 
if an animal resisted all intubation attempts, it was released and not used again. The 
volume that was introduced into the stomach was kept to a maximum of 100 µI. 
2.1.5 Removal of the Fetal Brain 
On day 181 / 2 post conception (p.c.) the pregn
ant mice were reweighed and then 
sacrificed by cervical dislocation. The pregnancies were not allowed to continue to 
term, because newborn mice with abnormalities are usually cannibalized by the 
mother. Laparotomy was performed and the uterine horns exteriorized and extended. 
The fetuses were carefully dissected out, and the number of live, dead and resorbed 
fetuses were recorded. Each fetus was blotted dry, weighed, and examined 
macroscopically for abnormalities. The fetal brains were dissected out, weighed, and 
placed in cryotubes. They were then stored at -196°c. 
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2.2 Sample Solubilization 
After retrieval from storage, the frozen tissue sample was dropped into solubilizin
g 
fluid. Thawing was hastened by agitation, and homogenization was begu
n 
immediately to minimize the action of proteases. The volume of solubilizing fluid wa
s 
adjusted to 20 µI per mg brain weight. 
Solubilization was undertaken with "UKS solution" (Damerval et al., 1986), consistin
g 
of 9,5 M urea, 5mM K2co3, 1 ,25% sodium dodecyl sulphate, 0,5% dithiothreito
l, 0, 1 
mM phenylmethylsulphonyl fluoride (PMSF), 2% Ampholines pH 3,5 to 10 (LK
B 
Bromma), and 6% Triton X-100. K2co3 was first used for protein solubilization by 
Horst and co-workers (1980) to augment the solubilizing properties of 9,5M urea o
n 
membrane proteins. 
Until fairly recently, the use sodium dodecyl sulphate in tissue solubilization wa
s 
avoided because of suspected interference with isoelectric focussing. Howeve
r, 
Wilson and co-workers (1977) used 1 % sodium dodecyl sulphate successfully in th
e 
solubilization and two-dimensional resolution of proteins from a eukaryotic sampl
e. 
O'Farrell (1975) reported that small amounts of sodium dodecyl sulphate may be use
d 
without detriment because during isoelectric focussing much of the deterge
nt 
separates from the protein and forms mixed micelles with Triton X-100. These micell
es 
migrate to the acidic end of the gel and in this way interference by the highly charge
d 
molecule with the pH gradient is avoided. 
Homogenization, using a Teflon pestle in a glass barrel, was continued until all sol
id 
bits of tissue had been fragmented. The sample was then sonicated with a prob
e. 
Three five-second bursts were usually sufficient to produce a uniform samp
le 
consistency. Pauses were allowed for local heating to disperse. It is particular
ly 
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important to avoid heating a urea solution, since heating may lead to isocyanate 
formation and the carbamylation of proteins (O'Farrell , 1975). 
After sonication the sample was centrifuged at 35 000 g for 15 minutes to remove 
cellular debris. To prevent the crystallization of urea, the temperature during 
centrifugation was maintained at 20°c. 
at -196°c. 
The supernatant was collected and stored 
The total protein concentration of the supernatant was 5 mg/ ml. The Folin phenol 
method of protein determination (Lowry et al., 1951) was not used as originally 
described, due to the presence in the protein sample of interfering substances. A 
modification was therefore used which included a deoxycholate-TCA protein 
precipitation step (Peterson, 1977). Once the supernatant containing the interfering 
substance was discarded, the Folin phenol method of protein determination was used 
on the re-dissolved protein. 
2.3 lsoelectric focussing 
2.3.1 Principles 
The first stage of the two-dimensional gel electrophoresis of a complex mixture of 
proteins is separation on the basis of charge. Every protein has a native charge, 
which is the sum of the positive and negative charges on the side groups of the amino 
acids that constitute the protein. If two different proteins cannot be resolved because 
they have the same charge, then they may be separated in the second dimension on 
the basis of differences in molecular weight. 
Whether an amino acid side group is charged or not depends on the pH of the 
immediate environment. For example, a highly acidic environment will make protons 
available for the ionization of groups of high pKa (amino groups) , and a highly alkaline 
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environment will remove protons from groups of low pKa (carboxyl groups). The 
number of charges on a particular protein, and whether they are negative or positive, 
may therefore be manipulated by changing the pH of the environment. When the pH of 
the environment is such that the protein molecule has no nett charge, then that 
particular pH is the isoelectric point (pl) of the protein. 
In an isoelectric focussing gel, the protein (or in this case, protein mixture) migrates 
through a pre-existing pH gradient under the impetus of an electric field. As the 
migration proceeds, the protein moves into an environment of either increasing pH or 
decreasing pH, and the state of ionization of the amino acid side groups changes. 
Should it happen that a point is reached where the protein has no nett charge, then 
migration will cease; the protein is at its isoelectric point. 
The pH gradient is established during pre-electrophoresis. pH gradients may be 
generated using a mixture of ordinary buffers that will have the required spread of pKs; 
these are "natural" gradients (Ander Lan and Chrambach, 1981). More usually pH 
gradients are generated from synthetic elements (ampholytes) that provide both an 
increase in resolving power and heightened stability of the gradient. Ampholines (LKB 
Bromma) are made from a mixture of oligoamines that are reacted with unsaturated 
compounds, mainly acrylic acid, giving a highly complex mixture of aliphatic oligo-
amino oligo-carboxylic acids (Righetti et al., 1986). These acids can be designed in 
such a way as to give a wide and continuous pH range, as well as having buffering 
and conductance properties. 
The principle that makes a pH gradient possible rests on the fact that when a single 
ampholyte species is dissolved in water the pH value is changed towards the isoionic 
point of the ampholyte (isoionic point is the pH value at which the net charge of the 
ampholyte is zero). So, when two or more ampholytes with different isoionic points 
are dissolved in water, the pH value obtained will fall within the range defined by the 
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isoionic points of the ampholytes (Schafter-Nielsen, 1986). When the current is 
switched on, ampholytes with isoionic points above the pH of the gel (positively 
charged) will migrate towards the cathode, and those with isoionic points below the 
pH of the gel (negatively charged) will migrate towards the anode. As the ampholytes 
migrate the local pH of the gel will change, since the local pH is defined by the isoionic 
points of the ampholytes themselves. Eventually the pH will form an even gradient 
from ampholytes with high isoionic points to those of low isoionic points. A steady 
state is reached due to the fact that the electrophoretic migration of the constituents of 
the electrode reservoirs is exactly balanced by their influx due to passive diffusion. 
The polyacrylamide gel in the isoelectric focussing tube must be "non-restrictive" to 
enable proteins to reach their pl. The migration velocities of proteins decrease as 
they approach their pl (charge approaches zero), and at low velocities the frictional 
effects of the matrix are exaggerated. A highly restrictive gel may therefore halt 
migration before the isoelectric point is reached. 
2.3.2 Apparatus 
In this study, large, non-standard gels were used. Large gels offer at least two 
advantages over the standard "O'Farrell" gels; more proteins can be loaded onto large 
gels, and large gels have a greater separation area (Colbert and Young, 1986). 
To produce large gels, standard electrophoretic equipment had to be modified or 
scaled up. Compared to the standard isoelectric focussing tube, the tubes used in 
this study were both longer and thinner (225 mm long; 2,5 mm internal diameter). The 
tubes were cut from lengths of Pyrex capillary tubing. Although the longer, thinner 
gels were difficult to manipulate, they offered the advantage of more efficient heat 
dispersion (small cross-sectional area), and made possible the application of higher 
voltages over a longer period of time. 
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Perspex components were made to specification by the Department of Biomedical 
Engineering, University of Cape Town Medical School (Fig. 1 ). The glass tubes 
passed through the floor of the upper chamber, and rubber grommets were used to 
hold them in place and to seal the chamber. The perspex top chamber holding the 
glass tubes and both electrodes was lowered into a three litre glass beaker containing 
the lower electrode solution. The three litre beaker was in turn lowered into a five litre 
beaker, and the space between the two beakers was used for the circulation of 
cooling water. A high volume of tap water was used for cooling; chilled water was 
tried but made no discernible difference to the quality of the gels. 
Because platinum is so expensive, palladium was used for electrodes. The apparatus 
was connected to the power source (Hoefer PS1200) with wiring and plugs supplied 
by the Department of Biomedical Engineering. 
2.3.3 Methodology 
The glass tubes used in isoelectric focussing were carefully treated to ensure optimal 
binding between the surface of the glass and the gel, and to ensure reproducibility. 
Between runs the tubes were stored in chromic acid. On the day before isoelectric 
focussing they were rinsed thoroughly with distilled water, and any remaining acid was 
neutralized by dipping the tubes into a methanolic alkaline solution. The tubes were 
once more thoroughly rinsed in distilled water, and then sialinized with a 1 % solution of 
dimethylchlorosilane in toluene. This process coats the surface of the glass with 
methoxy-silane groups, which reduces the adherence between the gel and the glass. 
Sialinization was essential because the narrow diameter and the length of the glass 
tubes made it impossible to otherwise remove the gels after electrophoresis. On two 
occasions all the gels slipped out of the tubes during electrophoresis. It is not known 
whether the cleaning and sialinization methodology was responsible for this. 
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The gel mixture used was essentially that developed by O'Farrell (1975). To have 
enough gel mixture to fill all the tubes of the apparatus the following recipe was used: 
To 8,25 g urea was added 2 ml of acrylamide stock, 3 ml of 10% Triton X-100, and 3 ml 
of water to which had been added 0, 75 ml Ampholines (0,6 ml pH 5-7, 0, 15 ml pH 3-
10). Acrylamide stock of 30% incorporated 1,4% bisacrylamide i.e. 30%T, 1.4%C. 
The amount of bisacrylamide determines the density of cross-linkage between 
acrylamide polymers, and is therefore one of the critical parameters in achieving good 
resolution. In the present system less bisacrylamide was used than was used by 
O'Farrell in order to improve the resolution of high molecular weight proteins. 
The gel mixture was vigorously swirled in order to dissolve the urea. Due to the 
possibility of carbamate ion formation, heating of the mixture was avoided. Once all 
the urea was dissolved, 15 µI of freshly made 10% ammonium persulphate was added. 
The gel mixture was placed under a partial vacuum for 2 minutes to allow dissolved 
gasses to boil off (oxygen inhibits polymerization). Finally, 10,5 µI of TEMED (N,N,N
1, 
N1 -tetramethyl ethylenediamine) was added, and the mixture was briefly swirled. 
The narrow internal diameter of the glass tubes and their hydrophobic surfaces (due to 
sialinization) made it impossible to fill the tubes using a needle and syringe. Instead, 
the gel mixture was drawn up into the tubes using a rubber bulb, and the filled tubes 
were then stoppered with rubber bungs. Care was taken to avoid the entrapment of 
any air bubbles inside the gel. The tubes were filled smoothly with one movement to 
ensure that polymerization was uniform. To keep the tubes steady and vertical they 
were pushed through the rubber grommets. The gel mixture was brought to about 1 O 
mm of the top of the tubes, and a small volume of 8M urea was layered onto the top of 
the gel mixture to act as an air seal. 
Gels were allowed to polymerize for 1,5 hours. During this time the lid was kept on the 
top chamber to prevent crystallization of the 8M urea used as a seal. After 1,5 hours 
40 
the urea was removed with a syringe, and replaced with 20 µI of Lysis Buffer (O'Farrell, 
1975) per gel , which was then overlayered with a small volume of water. The UKS 
solution, which was used in the sample solubilization, was not used in place of Lysis 
Buffer, since it is important in isoelectric focussing to keep the use of sodium dodecyl 
sulphate to a minimum. Gels were allowed to polymerize for a further 1,5 hours. 
The bottom tank was filled with three litres of 0,01 M H3P04. The buffer for the top 
chamber (0,03M NaOH) was prepared by boiling off dissolved CO2 in a partial 
vacuum. At the end of the polymerization time, the bungs were removed from the 
bottom of the tubes, and the Lysis Buffer from the top of the tubes. 20 µI of fresh Lysis 
Buffer was applied to the top of the gel, and the tubes were then filled to the top with 
NaOH. The perspex disc holding the tubes (Fig. 1) was placed on top of the bottom 
tank, and any air bubbles trapped at the bottom of the tubes were removed. The top 
chamber was filled with NaOH, and the apparatus connected to the power source. 
Before isoelectric focussing of protein samples could commence it was necessary to 
establish the pH gradient. During the process of pre-electrophoresis the voltage was 
increased in a step-wise fashion, as in O'Farrell (1975): a) 200 volts for 15 minutes; (b) 
300 volts for 30 minutes; and (c) 400 volts for 30 minutes. Cooling was provided by a 
continuous flow of tap water at room temperature. During the course of pre-
electrophoresis the current typically decreased from 1, 7 mA to 1 , 1 mA. 
Once the pH gradient had been established, the apparatus was switched off and the 
NaOH in the top chamber was poured off. The Lysis Buffer was removed from the 
surface of the gel. It was essential that all the fluid was removed since any remaining 
fluid would dilute the protein sample which would affect resolution and reproducibility. 
Protein samples were loaded on by means of a syringe, and a volume of 40 µI (200 µg 
protein) was used throughout. It was found that 200 µg protein was enough to make 
the detection of a large number of spots possible, without causing excessive streaking 
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due to overloading. The protein sample was overlayered with 10 ~I of 9M urea. 
Freshly degassed 0,03M NaOH was used to top up the tubes and to fill the top 
chamber. 
Electrophoresis of the proteins was commenced as soon as possible after the 
establishment of the pH gradient. Gels were run at 10 000 Vh, comprising 23 hours at 
400V, and one hour at 800V. The purpose of the final hour of isoelectric focussing 
was to achieve fine focussing of protein bands; it was never extended beyond one 
hour because of risk of obtaining distorted protein bands due to heat build-up. Water 
recirculation took place throughout the 24 hours of electrophoresis. 
After electrophoresis was concluded, the apparatus was disassembled and the glass 
tubes were pushed out of the grommets. Gels were extruded from the tubes by water 
under pressure from a syringe. The gels were dropped into glass test tubes each 
containing 7,5 ml of SOS Sample Buffer (O'Farrell, 1975), consisting of 10% glycerol, 
2,3% sodium dodecyl sulphate, 0,0625M Tris HCI (pH6,8) , and 5% 2-mercaptoethanol. 
The tubes were stoppered and rocked back and forth a number of times to facilitate 
the diffusion into the gel of the reducing and precipitating agents contained in the 
buffer. This critical process must be done as soon as possible after the conclusion of 
electrophoresis in order to minimize any protein diffusion. 
The test tubes containing the gels were stored in a freezer at approximately -20°c. 
Gels were stored in this manner for up to a week without loss of resolution. Storage of 
polyacrylamide gels in liquid nitrogen was not practised because of the frequency of 
gel fragmentation. 
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2.4 SDS Polyacrylamide gel electrophoresis 
2.4.1 Principles 
A polyacrylamide gel may be thought of as an open-meshed three-dimensional lattice 
which has ideal anti-convection properties as well as a poor affinity for sample 
molecules. The lattice structure arises from the polymerization of acrylamide monomer 
into long chains and the cross-linking of these by the bi-functional compound N 1, N 
1-
methylene bisacrylamide. The density, or pore size, of the lattice can be varied by 
changes in the concentration of acrylamide monomer as well as changes in the 
amount of bisacrylamide. Protein molecules migrating through the lattice are subject 
to frictional forces and are selectively retarded (and hence separated) according to 
molecular size. 
Gradient gels were used because of the advantages they offer in terms of versatility 
and resolving power. In a gradient gel the concentration of acrylamide varies (in this 
case, linearly) from one end of the gel to the other. The gel therefore has a range of 
pore sizes, and will accept a wider range of molecular sizes than a gel of uniform pore 
size. Gradient gels also offer enhanced resolution; as the proteins migrate into areas 
of decreasing pore size, the advancing edge of the migrating protein zone is retarded 
more than the trailing edge, resulting in a marked sharpening of protein bands 
(Hames, 1981 a). 
A discontinuous (or multiphasic) buffer system was used. In the discontinuous 
system, the buffer within the gel differs from the buffer in the electrode reservoirs. For 
example, Tris/HCI was used in the gel, and Tris/Glycine in the reservoirs. The pH was 
also "discontinuous" - the pH of the reservoir buffer was 8,3 while the pH of the 
stacking gel was 6,8 and the pH of the resolving gel was 8,8. 
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The advantages in having a discontinuous buffer system can be seen by examining 
what happens to the relative ionic mobilities during electrophoresis. At the pH of the 
stacking gel (pH 6,8), glycine is poorly dissociated and its mobility is low. Chloride 
ions, on the other hand, have a high mobility at this pH, whilst the mobilities of proteins 
are intermediate. The chloride ions therefore migrate away from the glycine, creating 
a "moving boundary", behind which there is a steep voltage gradient. The proteins, 
having a higher velocity than the glycine, are swept behind the moving boundary, and 
in the zone of steep voltage gradient they become concentrated into very thin zones, 
or "stacks". This "stacking" of the proteins is largely independent of the initial protein 
concentration (Hames, 1981b), and is a direct outcome of having a discontinuous 
buffer system. 
When the moving boundary reaches the resolving gel, the pH increases to 8,8. The 
glycine becomes more dissociated and overtakes the migrating proteins. At the same 
time, the gel pore size decreases markedly, and the proteins are retarded by 
molecular sieving. They now become "unstacked". While they migrate in a zone of 
uniform voltage and pH value, they are separated according to their intrinsic sizes 
(Hames, 1981c). 
Proteins that are resolved by means of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis are always dissociated. Secondary and tertiary protein structure is 
disrupted by sodium dodecyl sulphate and mercaptoethanol. . Sodium dodecyl 
sulphate avidly binds proteins (1,4g of sodium dodecyl sulphate per gram of 
polypeptide), resulting in a high density of negative charges on the polypeptide. The 
intrinsic charges of the polypeptide are insignificant compared to the negative charges 
provided by the bound detergent. Sodium dodecyl sulphate-polypeptide complexes 
therefore have essentially identical charge densities and migrate in the gel according 
to size rather than charge. It is impossible to draw conclusions about protein 
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conformation as a result of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, but it is relatively simple to determine the molecular weight of a 
polypeptide, which is an important criterion for identification. 
2.4.2. Apparatus for Casting and Running Slab Gels 
Slab gels with an area of approximately 400 cm2 were cast, which is more than twice 
the area of a standard gel. The slab gel apparatus was designed after O'Farrell 
(1975), and put together by the Department of Biomedical Engineering, University of 
Cape Town Medical School (Figure 2). 
It was essential to achieve a uniform gel thickness. Glass plates 4 mm thick were 
used to provide the necessary flatness. Thicker glass ( a laminated glass) was not 
used due to potential problems with heat dissipation. A bevelled edge was cut into 
one of the plates to hold the rod gel in position (as in Wilson et al., 1977). 
To assemble the apparatus, plastic spacers 1,5 mm thick were clamped between the 
glass plates along the sides and the bottom edge. The joints between spacers were 
sealed with a film of Celloseal (Hoefer). Before pouring the gel, the space between the 
plates was filled with water to show up any leaks. 
Gradient gels were made using a standard two-chambered gradient mixer (Hames, 
1981 d). A linear gradient is obtained if the two chambers are of equal cross-sectional 
area, and if the two volumes of acrylamide gel solution are equal. To prevent mixing of 
the solution once it had flowed into the gap between the plates a low flow rate from the 
mixer was maintained. 
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2.4.3 Slab Gel Methodology 
Electrophoresis grade acrylamide (BDH Electron) was used in the stacking and 
resolving gels. The stock solution (T30%, C1 ,6%) was filtered to remove any 
undissolved acrylamide, and when not in use was stored at 2-4°C. Fresh stock was 
made up every 6-8 weeks. 
An acrylamide gradient of 6-17% was utilized to resolve the proteins in the fetal brain 
sample. 64 ml of the running gel mixture was made up. The recipe for the mixture 
closely follows O'Farrell (1975)(See Table 2.1). There were, however, a number of 
modifications. Buffer A was made up with 50% glycerol (not 75% as in O'Farrell) 
because of solubility difficulties. No sodium dodecyl sulphate was included in the 
resolving gel ( or in the stacking gel) because it was found that protein patterns were 
sharper when sodium dodecyl sulphate was not included. This is a paradoxical result 
without a ready explanation (Bloemendal and Jansen, 1986). Ammonium persulphate 
was made up freshly on the day of use. 
The stock acrylamide and Buffer A (or Buffer B) were pipetted into a 50 ml measuring 
cylinder, and the volume was brought up to 32 ml with distilled water. The gel 
preparation was then mixed by inverting the measuring cylinder, as it was after the 
addition of the ammonium persulphate and the TEMED. The 17% acrylamide mixture 
was poured into the front chamber of the gradient mixer immediately after adding the 
TEMED Great care was taken to follow a uniform procedure to ensure reproducibil ity 
in the gel gradient. The mixture was allowed to trickle into the gap between the 
plates at a rate of about 4 ml per minute. The gap was filled up to about 3 cm of the 
bevelled edge. A few drops of water were carefully pipetted onto the top of the gel to 
act as an air seal. After about 1,5 hours the gel was checked for the presence of a 
clear phase transition between gel and water, an indication that polymerization had 
occurred. 
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The stacking gel mixture was prepared (see Table 2.1). The water layer was 
removed from the top of the resolving gel, and the stacking gel mixture was poured 
from the measuring cylinder onto the top of the resolving gel, up to the bevelled edge. 
A few drops of water were pipetted onto the unpolymerized stacking gel to act as an 
air seal. Any gel mixture that was left over in the measuring cylinder was set aside to 
serve as an indication of polymerization. 
Once the stacking gel had polymerized, the clamps were removed from the bottom of 
the glass plates and the plastic spacers along the bottom edge were pushed out. 
Tank Buffer consisting of 0,03% Tris, 1,44% glycine, and 0,01 % sodium dodecyl 
sulphate was poured into the bottom tank and the apparatus containing the gel was 
lowered into the tank buffer. Any air bubbles in the space at the bottom of the gel 
were removed. The bottom tank was filled up until the buffer reached the top of the 
resolving gel (the buffer had a cooling function). 
A frozen rod gel was removed from storage and allowed to thaw gently . 30 ml of 
fresh SOS Sample Buffer (see section 2.3.3) was brought to the boil. When the rod 
gel had thawed, the beaker containing the SOS Sample Buffer was removed from the 
flame and the rod gel was dropped into the hot solution, where it was allowed to 
equilibrate for 5 minutes. 
Preparations were now ready to anneal the rod gel to the slab gel. The thin layer of 
water was removed from the surface of the stacking gel. This was replaced with a 
thin layer of molten 1% agarose (LKB Bromma, electrophoresis grade) in SOS Sample 
Buffer. The rod gel was lifted from the hot SOS Sample Buffer, and using a folded 
sheet of Parafilm, was manoeuvred onto the layer of molten agarose. The bevelled 
edge of the glass plate prevented the rod gel from slipping off, and made it possible to 
envelop the entire rod gel with agarose, annealing it into position. It was extremely 
important that no air remained trapped between the rod gel and the slab gel. 
Table 2.1 Recipe for Resolving and Stacking Gel 
Stock acrylamide (ml) 
Buffer A (ml) 
Buffer B (ml) 
Stacking buffer (ml) 
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Once the agarose had set, the top chamber was filled with Tank Buffer. This was 
done slowly to avoid creating turbulence that could have disturbed the seating of the 
rod gel. A few drops of 0, 1 % bromophenol blue were added to the top chamber to 
provide a visible migration front during electrophoresis. 
Molecular weight standards (see Appendix) were pipetted into a pre-formed notch in 
the agarose, or were run separately on slab gels that were identical to the slab gels 
used in the second dimension. For the sake of simplicity molecular weight standards 
were not run with every test gel. 
Electrophoresis was now ready to begin. The power pack was set at 30mA per gel on 
"Constant Current" although it was also possible to do the run on "Constant Voltage", 
beginning at 100V. Electrophoresis lasted for 14 hours. Cooling was not necessary. 
At the end of the run the clamps were removed and the glass plates prised apart. 
The stacking gel was separated from the resolving gel and discarded. The resolving 
gel was immediately placed in a staining solution to avoid excessive surface drying. 
Gloves were always worn when handling gels. All resolving gels were stained with 
Coomassie blue as a matter of course. 
2.5 Visualization of protein patterns 
2.5.1 Coomassie blue staining 
Coomassie blue dyes provide a quick and inexpensive method for the visualization of 
protein patterns on polyacrylamide gels. Although Coomassie blue is by no means 
the most sensitive stain available, in this study it was routinely used to stain every gel. 
The advantage this offered was that unsatisfactory gels could be identified before 
subsequent, more time-consuming, visualization procedures were embarked upon. 
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To make up the staining solution, 0,25% Coomassie blue R was dissolved in 40% 
methanol and 10% trichloroacetic acid (Neuhoff et al., 1985). This is only one of a 
host of different Coomassie blue staining procedures, and was selected for speed and 
simplicity. The R form of Coomassie blue (Colour Index 42660), obtainable from Sigma 
Chemical Company, is considered to be superior to other forms of the dye (Wilson, 
1979). A high percentage of trichloroacetic acid and methanol in the staining mixture 
ensure that the proteins remain precipitated during staining; methanol also assists in 
the penetration of the dye into the gel. 
Staining was allowed to proceed for an hour with constant agitation. After one hour 
the staining solution was discarded and the gel destained with a 5% methanol and 7% 
acetic acid aqueous solution. The destaining solution was changed every 30 minutes. 
After approximately three hours the gel was destained to the point where all the major 
spots could clearly be seen. 
2.5.2 Silver Staining 
The visualization of proteins on gels by means of silver staining is clearly superior to 
any of the detection methods using Coomassie blue. Literature reports claim that in 
terms of sensitivity, silver staining has the potential to give a fifty to one hundred fold 
improvement over Coomassie blue staining (Merril et al., 1981; Oakley et al., 1980; 
Switzer et al., 1979). Nielsen and Brown (1984) claimed that the detection on a gel of 1 
ng of protein is feasible. There have in fact been claims of detection limits of 
sensitivity well below 1 ng protein. For example, Morrissey (1981) managed to detect 
42 pg of protein, and Ohsawa and Ebata (1983) claimed a detection limit of 1 O fg 
protein. Silver staining has been refined to the point where it is now comparable in 
sensitivity to autoradiography of 35s-methione-labelled proteins (Sammons et al. , 
1981), and 14C-labelled proteins (Switzer et al., 1979; Merril et al., 1981). 
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In this study, there was a four-fold increase in sensitivity of silver staining over 
Coomassie blue staining, in terms of the number of countable protein spots. 
Approximately 1250 different proteins were detected on wet gels immediately following 
silver staining. 
Methodology: Numerous silver staining protocols have been published. Many of 
these propose minor improvements over previously published methods. Generally, 
silver staining methods may be divided into two categories: those that rely on an 
alkaline environment (Oakley et al., 1980) and those that rely on a weak acid 
environment (Sammons et al., 1981; Merril and Pratt, 1986). The method chosen for 
the detection of fetal mouse brain proteins was that of Guevara and co-workers (1982). 
It is a development of the procedure of Oakley and co-workers (1980) in that it utilizes 
ammoniacal silver. It was found to be extremely sensitive and had the additional 
attraction of giving low background staining. 
A detailed method description is followed by a discussion of some of the steps: 
Step 1 After electrophoresis, gels were placed in a 20% ethanol solution containing 
5% v /v acetic acid, and 2,5% w /v sulfosalicylic acid (400 ml per gel) for at least 12 
hours with one solution change. 
Step 2 Gels were washed in 20% ethanol (Merck) 3 times, 400 ml per gel, for 20 
minutes each. 
Step 3 Gels were placed in a 20% ethanol solution (400 ml per gel) containing 5,9 
mmol silver nitrate, 31 mmol ammonium hydroxide, and 2,8 mmol sodium hydroxide, 
and were equilibrated for 1 hour. 
Ammoniacal silver hydroxide solution was prepared by adding 4,2 ml 14,8M 
ammonium hydroxide, 0,226 g sodium hydroxide and 80 ml absolute ethanol to 296 ml 
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high purity, distilled water. Silver nitrate (2,0g) was then dissolved in 20ml water and 
added dropwise to the ammoniacal-ethanol solution, with vigorous agitation. 
Step 4 Gels were rinsed in water; then step 2 was repeated. 
Step 5 Gels were placed in a 20% ethanol solution (400 ml per gel) containing 0,01% 
citric acid and 0,037% formaldehyde "developing solution". Images appeared within 
5 minutes and development was allowed to proceed for up to 30 minutes. 
Step 6 Development was terminated by placing the gels in 500 ml 20% ethanol and 
0,5% acetic acid for 30 seconds. 
Step 7 Gels were washed in running tap water for 45 to 60 minutes. 
Promising gels were stained twice to develop some of the fainter spots. This was 
accompanied by the overdevelopment of major spots, but did lead to the visualization 
of protein spots that failed to show up after the first staining. Quantitation of the spots 
by means of densitomitry was not contemplated because of the ease of recognizing 
pattern changes visually, and because densitometry is inadequate in the analysis of 
very faint spots (Hochstrasser et al., 1986). 
Washing of Gels To obtain a low background staining, gels were extensively 
washed. 20% ethanol prevents the diffusion of proteins out of the gel, and also 
assists in the removal of the low molecular weight components that increase 
background staining; these include Tris, glycine, sodium dodecyl sulphate, glycerol, 
carrier ampholytes, and sulfhydryl reagents viz., dithiothreitol and 2-mercaptoethanol 
(Guevara et al. , 1982). Electrophoresis grade agarose was used to anneal the rod 
gels to the slab gels, since impurities in the agarose will contribute to a high 
background staining (Amess et al., 1985). At every stage of silver staining high purity 
water (MilliQ - Millipore), with a resistivity of 10 megaohm.cm. , was used. 
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Some brands of ethanol were unsuitable, giving uneven development with a rapid, 
intensely black staining. The problem was traced to the presence of aldehyde in the 
ethanol which caused premature reduction of the silver, and its precipitation out of the 
solution, resulting in high surface staining. Ethanol supplied by Merck S.A. was found 
to be free of this problem. 
Colour Formation The silver staining method of Guevara and co-workers (1982) 
gave spots that were predominantly brown, orange and yellow, with some black and 
reddish spots. Sammons and colleagues(1981) described a modified silver staining 
procedure for enhancing colour differences, with the view to exploring the possibility 
that protein subclasses may be identified by colour alone. This possibility has not 
been realized, however, but colour differences do appear to reflect differences in the 
amino acid composition of proteins. For example, Chuba and Palchaudhuri (1986) 
found that proteins without cysteine do not stain on a gel at all. They were not 
however, able to correlate colour with mole percentage of cysteine in various proteins, 
and there must be additional factors that have a bearing on colour formation. If silver 
ions do show more affinity for some amino acids than others, then that would explain 
the poor correlation of protein concentration with grain density between different 
proteins (Yuksel and Gracy, 1985). 
Mechanism Silver staining is initiated by the formation of a metal ion complex with 
available moieties on the protein, followed by the reduction of the complexed ionic 
silver to metallic silver. The electron-donating properties of the biochemical groups 
are not sufficient for the reduction of the silver ions, and all the silver staining 
procedures need either additional photo- or chemical-reduction agents to produce a 
metallic silver image (Merril and Pratt, 1986). In the method of Guevara and co-
workers (1982), an alkaline pH is maintained at protein clusters by ionic retention of 
ammoniacal silver ions and hydroxyl ions. The electrons for the reduction of 
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ammoniacal silver ions to metallic silver is provided by the oxidation of formaldehyde 
to formic acid. Citrate is an anti-oxidant, and attenuates the rate of formaldehyde 
oxidation, thereby preventing the deposition of black "dust" on the surface and 
throughout the gel. 
2.5.3 Fluorography following Reductive Methylation 
The detection of radiolabelled proteins on a gel by means of an X-ray plate is an 
effective way of visualizing constituents at very low detection limits. In this study 
fluorography was attempted in order to achieve even greater sensitivity than silver 
staining. The advantage of fluorography is that an image may be developed for as 
long as necessary in order to visualize areas of the gel that contain a host of very faint 
spots. However, success was limited, and the difficulties that were encountered will 
be discussed below. 
It was not practical to radiolabel proteins by utilizing the metabolic incorporation of 
labelled amino acids by the living animal. Feeding animals with labelled amino acids 
is prohibitively expensive due to the dilution of the sample by non-target tissue in the 
mother and the fetus. A more realistic strategy was to transfer the radiolabel by purely 
chemical means onto proteins that have been solubilized. Unfortunately, however, 
chemical labelling of proteins is less efficient than labelling by the utilization of 
metabolic processes, and entails the modification of the native protein. 
Reductive methylation using cyanoborohydride is an established method for the 
transfer of radioactive alkyl moieties onto free amino groups of proteins (Means and 
Feeney, 1968). This reaction, which occurs in the presence of a reducing agent, takes 
place specifically at the E-amino group of lysyl residues, and the amino groups at the 
N-terminus of the peptide. As many as 8,5% of amino acids of proteins have lysyl 
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residues; reductive methylation has therefore the potential for the effective labelling of 
proteins. 
The radiolabel 50mCi of tritiated sodium cyanoborohydride with a specific activity of 
195,2mCi/mg was obtained from Amersham. The vial contained 0,2561 mg of tritiated 
material, and was diluted tenfold with non-tritiated sodium cyanoborohydride, giving a 
total of 2,561 mg. A stock solution of 6 mg/ml was made up by adding 426,8 ml of 
buffer to the vial. The buffer was 50 mM sodium phosphate pH 7,0. The stock was 
divided into aliquots and frozen at -20°c. 
The reaction. The carbon atom for the methylation reaction is derived from 







) .., Protein-N-(CH3)2 
NaBH3CN 
The reaction of formaldehyde with a free amino group produces a Schiff base; this 
reaction passes through two cycles. The secondary amine is a minor product of the 
reaction, and is less stable than the tertiary amine, a dimethyl derivative (Means, 1977). 
The reaction was buffered with a phosphate buffer, but borate, EDT A, and Hepes 
buffers are also suitable (Jentoft and Dearborn, 1979). Ammonia ions, or primary 
and secondary amine buffers (like Tris) cannot be used because they undergo 
alkylation themselves. 
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Tissue solubilization Some protein solubilizing reagents inhibit the reductive 
methylation reaction (Jentoft and Dearborn, 1979). For example, sulfhydryl 
compounds form adducts with formaldehyde thus lowering the available reagent. 
There is no significant inhibition of the methylation reaction in the presence of SM urea, 
but 1 % sodium dodecyl sulphate has a marked effect on the transfer of the label onto 
protein. Inhibitory effects that are pronounced after two hours of reductive methylation 
are invariably much less so after 24 hours. To achieve efficient labelling at the same 
time as achieving efficient solubilization, it was necessary to have the methylation 
reaction over an extended period of time. 
The solubilization fluid consisted of SM urea, 0,5% sodium dodecyl sulphate and 5% 2-
mercaptoethanol, used at 20 ul/mg of brain tissue. After homogenization and 
sonication (protein concentration 5mg/ml), the sample was diluted 1 :5 with Na+ 
phosphate buffer (pH 7,0). To 600 ul of sample was added 80 ul HCHO and 80 ul of 
sodium cyanoborohydride. The mixture was shaken overnight. 
Removal of unreacted label. After reductive methylation all unreacted label had to be 
separated from the sample to prevent free label contaminating the gel. In addition, to 
achieve high resolution separation of proteins during isoelectric focussing, the sample 
had to be desalted. Two methods were attempted: 
(a) Precipitation of proteins. Trichloroacetic acid is commonly used (for example, see 
Jones and Vidaver, 1981). The reaction mixture was brought up to 10% with ice-cold 
trichloroacetic acid, thoroughly mixed, and placed in an ice-water mixture for 10 
minutes. After centrifugation at 1 O OOOxg for 5 minutes, the supernatant was 
discarded and the pellet washed twice with ethanol: ether (1 :1). However, 
resolubilization of the pellet was impossible, even after dispersal in a solubilizing 
solution with sonication. Resolubilizing strategies included the use of Lysis Buffer, 
Lysis Buffer plus 1% sodium dodecyl sulphate, and 9,5M urea plus CHAPS 
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([Cholamidopropyldimethylammonia ]-1-propanesulphonate). The failure to achieve 
resolubilization was attributed to the formation of insoluble beta-sheets during 
precipitation (Prof. W Brandt, personal communication). The use of acetone in the 
place of trichloroacetic acid did not help. 
(b) Dialysis is the most frequently used method for removing unreacted label and for 
desalting samples (see for example, MacKeen et al., 1979) and was utilized in the 
present study. Spectrapor membrane tubing (10 mm wide) was used, with a 
molecular weight cut-off of 12 000 - 14 000 daltons (pore size 4). The sample was 
dialised against distilled water for 12 hours at 4°C. Once dialysis was complete, the 
contents of the membrane tubing was mixed with an equal volume of UKS solution 
(see section 2.2). The sample was then applied to the isoelectric focussing gel. 
Fluorography After electrophoresis gels were stained with Coomassie blue, and 
extensively destained with 5% methanol and 7% acetic acid in water (to wash out all 
trichloroacetic acid). To impregnate the gels with a scintillator, the gels were 
immersed in Amplify (Amersham) for 30 minutes with constant agitation. The gels 
were removed and dried onto cellophane using a gel dryer. Once dry, the cellophane 
was pulled off and the dried gel was firmly pressed down on pre-flashed X-ray plate 
(Kodak X-omat) and clamped into position. The cartridge was kept at -20°c for 7 
days, after which the x-ray plate was developed. 
The results, however, were disappointing, and fluorography as a means of 
visualization was not pursued. After fluorography even the major spots were slightly 
fuzzy, and some of the fainter spots were visible merely as smudges. The fuzziness 
may have been due to the fact that labelling involved protein modification, although the 
problem may have been due to shortcomings in the scintillator (Hames, 1981e). Silver 
staining gave superior spot quality and in addition was much quicker to perform and 
also cheaper than fluorography. 
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2.6 Storage and Documentation 
Gels that were stained with Coomassie blue were dried on a commercially available 
gel-dryer (Hoefer). Although the gels were considerably larger than standard gels, 
the dimensions had been chosen to make the large gels compatible with the available 
gel dryer. Coomassie blue-stained gels were dried onto a stiff plastic backing 
(Cronar clear base, 0, 1 mm). Due to heat and pressure during the drying process, the 
acrylamide gels annealed to the plastic, forming a permanent bond. The stiff plastic 
prevented gels from curling up or deteriorating in any way, and also facilitated storage. 
Silver stained gels were not dried, because drying appeared to intensify the 
background stain. Silver stained gels were stored as wet gels, in 20% ethanol, at 2-
40C. Gels could be stored in this manner for up to six months. 
Important gels were photographed. Because of the large number of extremely faint 
spots, a conventional SLR camera with a 35 mm negative was not used. Instead, 
photography was done by specialist photographers (Creative Colour Laboratory (Pty) 
Ltd), using an extra-large negative (100x125 mm). It was felt that this arrangement did 
justice to the exceptional resolving power of the two-dimensional electrophoretic 
system. 
2. 7 Statistical Analysis 
Differences between the offspring of control and treated females were tested by one of 
two methods. Differences in fetal weight and fetal brain weight were tested by the 
Student t-test. Differences in the frequencies of resorptions, intra-uterine deaths and 
malformations were tested by chi-squared analysis (Underhill, 1978). A 5% level of 
significance was chosen for all analysis. 
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CHAPTER 3 
MORPHOLOGIC ANOMALIES TO THE FETAL MOUSE, AND MOLECULAR 
CHANGES TO FETAL MOUSE BRAIN AFTER IN VIVO PHENYTOIN EXPOSURE 
3.1 Introduction 
3.1.1 The Fetal Hydantoin Syndrome 
Phenytoin has been in use as an anticonvulsant since 1938, and during the past 50 
years has been the single most effective drug for the treatment of most forms of 
epilepsy. The numerous adverse side effects of phenytoin have been carefully 
documented, but until recently there was little information about its teratogenic 
potential. Although phenytoin has been the drug of choice for pregnant epileptic 
women, it has been only over the last 15 years that the consensus has emerged that 
phenytoin, over and above the effects of the epilepsy itself, is potentially harmful to the 
fetus. There now appears to be little doubt that the ingestion of phenytoin during 
critical stages of pregnancy increases the risk to women of giving birth to a 
dysmorphogenic or retarded child. 
Meadow, in 1968, was one of the first to postulate an association between birth 
abnormalities and the use of phenytoin during pregnancy. He noticed a high 
incidence of cleft lip and cleft palate in children born to epileptic mothers on phenytoin. 
Other abnormalities included unusual facies and skulls, congenital heart lesions, and 
abnormalities of the peripheral skeleton. In a more recent study, Hanson and Smith 
(1975) examined five unrelated infants born to epileptic women who had been treated 
with phenytoin during pregnancy. They found a common multisystem pattern of 
abnormalities which they named the Fetal Hydantoin Syndrome. This syndrome 
includes craniofacial abnormalities, limb defects, and growth and mental deficiency. 
Hanson and Smith carefully documented all dysmorphic features, including those that 
were not necessarily medically or cosmetically significant. The craniofacial features 
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include short nose with low nasal bridge, inner epicanthic folds, ptosis, strabismus, 
hypertelorism, low-set ears, wide mouths, wide fontanels, and prominent lips. Some 
subjects had a short or webbed neck with or without a low hairline (features also noted 
by Meadow), and coarse hair. There were skeletal abnormalities of the ribs, sternum 
or spine, and appendicular defects including hypoplasia of the nails and distal 
phalanges, finger-like thumb, abnormal palmar creases, and five or more digital 
arches. 
Since these early reports, the existence or otherwise of the Fetal Hydantoin Syndrome 
has been carefully examined. Shapiro and colleagues (1977) judged that the 
association between hydantoin ingestion and birth abnormalities was unconvincing, 
and attributed the abnormalities described by Hanson and Smith to the epilepsy itself. 
In their reply, Hanson and Smith (1977) granted that epilepsy was a confounding 
factor, but reaffirmed their conviction that hydantoins are teratogenic. They were 
unable to find a single infant of an epileptic mother not treated with a hydantoin during 
pregnancy, that showed the full pattern of dysmorphogenesis which they refer to as 
the Fetal Hydantoin Syndrome. 
Although there is still some debate about the teratogenicity of phenytoin, it is 
becoming increasingly clear that infants born to mothers with seizure disorders treated 
with phenytoin during pregnancy are at an increased risk for congenital defects 
(Hanson, 1986). The full pattern of abnormalities sufficient to be recognised as the 
Fetal Hydantoin Syndrome is probably present in no more than 5 to 10% of exposed 
infants (Hanson et al., 1976). However, careful examination (including radiographic 
examination) for indications of altered growth and morphogenesis, may identify subtle 
prenatal hydantoin effects in an additional 30% or more of cases (Hanson, 1986). 
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3.1.2 The Fetal Hydantoin Syndrome and the Brain. 
There is not enough epidemiological data to decide whether phenytoin is a central 
nervous system teratogen. What information there is has been derived from the 
examination of infants born to women who took a number of different anticonvulsants 
during pregnancy. It is therefore impossible to separate out the teratogenic effects 
potentially due to phenytoin from those due to other anticonvulsants. 
The rate of central nervous system malformations in infants exposed to 
anticonvulsants before birth is not high. Schardein (1983), from a composite study of 
2168 infants whose mothers were on a number of different anticonvulsants during 
pregnancy, gives a malformation rate of 0,8%. This figure is in fact lower than the 
frequency of central nervous system abnormalities for children not exposed to 
anticonvulsants (1%). Schardein records a number of severe malformations among 
the 2168 infants in the composite study: one case of spina bifida, 5 of anencephaly, 4 
of hydrocephaly, 4 of microcephaly, and 4 of myelomeningocele. Unfortunately it is 
impossible to decide from the data whether the nature or incidence of the 
malformations differ between infants exposed to anticonvulsants during pregnancy 
and those not exposed. 
Many of the central nervous system malformations associated with infants exposed to 
anticonvulsants in utero may be secondary effects arising from malformations to the 
skull and the spine. Phenytoin has been strongly implicated in the abnormal 
development of the skull and the head. For example, Hanson and Smith (1975) 
included abnormal fontanels in the Fetal Hydantoin Syndrome, and Meadow (1968) 
noted abnormally shaped skulls. Lewin (1973) reported a malformed child born to a 
woman receiving both phenytoin and phenobarbitone during pregnancy, among other 
abnormalities the child had an encephalocele. It is therefore not impossible that cases 
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of exencephaly in fetuses exposed to phenytoin in utero arise from a prolonged delay 
in the closure of the skull. 
Microencephaly, accompanied by mental retardation, was recorded by McIntyre 
(1966) in two infants whose mothers had taken a hydantoin and another anticonvulsant 
in the 1st and 2nd trimesters. Likewise, Rating and Jager (1980) found postnatal 
microencephaly in children whose mothers had used phenytoin and phenobarbitone 
during pregnancy. On the basis of only two reports it is impossible to decide whether 
the ingestion of phenytoin on its own during critical stages of gestation is likely to 
increase the frequency of microencephaly in the offspring. It is also unclear whether 
microencephaly in children exposed in utero to anticonvulsants results primarily from 
growth suppression of the brain itself, or secondarily from growth suppression of the 
skull. Since reduced head size has been found in infants exposed in utero to 
anticonvulsants, microencephaly may be a secondary outcome to a suppression of 
the development of the bones of the head. 
Mental deficiency is a feature of the Fetal Hydantoin Syndrome, and includes both 
delayed motor development and intellectual impairment (Hanson and Smith, 1975). In 
addition, adaptive and personal skills are delayed (Seeler et al., 1979). Behavioural 
and intellectual impairment in these children suggest that phenytoin may have subtle 
teratogenic effects on the brain itself; the more catastrophic brain abnormalities may 
result from phenytoin effects on bone development. 
3.1.3 Phenytoin and the Fetal Brain : Experimental Approaches 
Literature reports dealing with the effects of phenytoin exposure on fetal neural tissue 
cover a range of experimental techniques, and include, inter alia, tissue culture, 
macroscopic anatomical studies, and behavioural studies. 
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Primary dissociated cell cultures from the cerebral cortex of 16-day fetal mice were 
used by Swaiman and co-workers (1982) to investigate the teratogenicity of phenytoin. 
After 7 days of exposure to phenytoin (15-50 µg/ml) there was a significant decrease in 
the number of neurones. Blank and co-workers (1982) found that phenytoin, when 
applied to developing neonatal mouse cerebellar cultures in concentrations from 9 to 
46 µg/ml, induced cerebellar cortical degeneration in a dose-dependent manner, with 
Purkinje cells the most susceptible. 
Using mouse embryo cultures, Bruckner and co-workers (1983) studied aspects of 
early embryogenesis. Embryos with one to seven somites were exposed in vitro to 15 
to 135 µg/ml of phenytoin for up to 42 hours; a dose-dependent inQrease in the 
frequency of abnormal embryos was found. Abnormalities included open neural 
tubes in the cranial regions and craniofacial deformities. A defect in the normal 
closure of the neural tube is considered to be a major factor in the development of 
exencephaly (Bruckner et al., 1983). These findings support the suggestion (made in 
section 3.1.2) that some of the severe brain abnormalities may result from closure 
defects. 
Hicks and co-workers (1983) found that phenytoin administered to fetal mice on day 10 
post conception, leads to altered DNA and protein synthesis in primary palates, which 
may explain the increased occurrence of cleft lip and cleft palate in fetuses exposed to 
phenytoin in utero. The same results were obtained for DNA and protein synthesis in 
limb buds. Interference with embryonic macromolecular synthesis by phenytoin may 
account for other teratogenic effects, such as open neural tubes and dysmorphology 
of the cranium. 
Flint and Orton (1984), in their "teratogen assay", exposed cultured cells from rat 
embryo midbrain and limb buds to a range of substances, including phenytoin. 
Teratogenic potential was judged from the extent to which differentiation of embryo 
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midbrain cells was inhibited. Phenytoin strongly inhibited cell differentiation. This 
inhibition took place at concentrations lower than those causing cytotoxicity - which 
gives a convenient distinction between a teratogenic and cytotoxic manifestation. 
Morphologic examinations of the fetal brain after in vivo phenytoin exposure have 
confirmed that phenytoin may be a central nervous system teratogen. Sullivan and 
MacElhatton (1977), as part of a detailed anatomical examination of fetal mice after in 
vivo exposure to anticonvulsants, found that phenytoin exposure was linked to 
increased incidence of exencephaly and enlarged cerebral ventricles. Harbison and 
Becker (1969) found, among other abnormalities, hydrocephalus and exencephaly 
(infrequently). Beyond suggesting that phenytoin is in fact a central nervous system 
teratogen, this experimental approach has not proved to be particularly fruitful. One 
reason is that the brain, although highly complex, has few external features that may _ 
be used as parameters in a teratology study. 
Behavioural deficits may be extensively studied in young or adult animals that have 
been exposed to teratogens pre-natally. For example, Mullenix and co-workers 
(1983) detected behavioural changes in rats that were exposed to phenytoin in utero. 
From a study of two different parameters - performance in a residential maze, and a 
variety of motor acts - it appears that prenatal phenytoin exposure may result in 
animals maintaining immature activity levels into adulthood. 
The results of these experiments show that a variety of changes may be induced in 
fetal neural tissue, obtained from the mouse and the rat, following phenytoin exposure. 
In the present study molecular manifestations of phenytoin teratogenicity were sought, 
since it was hoped that these would provide an insight at a fundamental level into the 
events that lead to injury to the fetal central nervous system. 
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3.1.4 Some Possible Mechanisms of Phenytoin Teratogenicity 
As with thalidomide, the mechanisms of phenytoin teratogenicity remain unknown, 
although a number of hypotheses have been advanced. 
The so-called folic acid antagonism hypothesis arose from the observation that folic 
acid levels are lower in the blood and the spinal fluid, of people on phenytoin 
medication (Berg et al., 1988). Folic acid is of critical importance as a co-factor in 
many metabolic processes. According to Reynolds (1973), subnormal values of folic 
acid occur in 91 % of women taking anticonvulsants and they may be even further 
lowered during pregnancy. Several folic acid antagonists are known human 
teratogens (Schardein, 1976). In some species of experimental animals folic acid 
antagonists and analogues readily induce congenital defects (Schardein, 1976). For 
example, rodents kept on a folic acid-deficient diet or exposed to folic acid 
antagonists will produce abnormal offspring (Schardein, ' 1976). There is therefore a 
definite association between the reduction by phenytoin of folic acid levels and a 
teratogenic effect. 
Various experiments have shown however, that the link between phenytoin induced 
folic acid depletion and a teratogenic outcome is tenuous. Netzloff and Rennert 
(1976) measured oxygen consumption along with folic acid levels in mouse embryonic 
cells following treatment with phenytoin. Both variables were reduced, compared with 
levels in the controls, and similar findings followed treatment with the folic acid 
antagonist, 9-methylpteroylglutamic acid. Moreover, experiments in which there was 
concurrent administration of folic acid plus phenytoin have been inconclusive (Kernis 
et al., 1973), suggesting the absence of a direct relationship between folic acid and 
phenytoin in relation to teratogenicity. Possibly phenytoin teratogenicity is mediated 
by effects on polyamine levels (via ornithine decarboxylase), and the folic acid-
antagonist effect is secondary (Buehler and Smith, 1979). 
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Some findings have implicated the epoxide metabolite of phenytoin in the mechanism 
of teratogenicity (Blake and Fallinger, 1976). It has been suggested that the reactive 
epoxide binds covalently to gestational tissue, thereby disrupting macromolecular 
functioning during critical periods of embryonic development (Spielberg et al., 1981). 
It is not possible to test this hypothesis directly, since the metabolite has yet to be 
isolated in sufficient quantities to be available for in vivo studies. The fact that some 
infants escape all teratogenic manifestations, despite prolonged in utero phenytoin 
exposure, may be due to a genetically determined ability of some fetuses to cope with 
harmful metabolites (Millicovsky and Johnson, 1981), either by the low production of 
the suspected harmful epoxide, or by its rapid excretion. 
3.2 Results 
3.2.1 Drug Administration 
Phenytoin sodium (8.P.) (Lennon Ltd) was suspended in distilled water and the pH 
adjusted to 7,6 using phosphoric acid (Patsalos and Wiggins, 1982). The drug was 
administered by gastric intubation (see Section 2.1.4) . The suspension was made up 
freshly on the day of administration. Controls received distilled water (pH adjusted to 
7,6) 
It was essential that the drug was administered during the critical period of teratogenic 
susceptibility. In the mouse, the development of the brain as an organ begins at 
approximately day 81 / 2 post conception (p.c.), with the development of somites and 
neuromeres (Rugh, 1968). However, it is between day 81/ 2 and day 9
1/ 2 p.c. that 
organogenesis is greatly accelerated, and according to Robert Rugh, "the most 
devastating congenital anomalies can be produced in embryos subjected at this time 
(day 81/ 2 to day 9 p.c.) to various types of trauma" (Rugh, 1968). On day 9 p.c. the 
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neural tube has largely closed, and the entire nervous system is undergoing cellular 
differentiation. It was therefore decided to administer phenytoin as single dosages on 
days 81 I 2 and 91 / 2 p.c. Both days fell within the period of greatest teratogenic 
susceptibility, and it was hoped that phenytoin administration on day 81 I 2 and day 
91 / 2 p.c. would produce markedly different teratogenic outcomes, due to the profound 
and rapid developmental changes taking place within the fetal brain during this period. 
It was also essential to select the dosage of phenytoin very carefully. On the one 
hand, too high a dosage causes maternal toxicity; on the other hand, enough drug 
had to be administered to show up any potential teratogenicity. The literature is not 
helpful because of the wide variety of experimental protocols that are described. Not 
only have several different strains of mice been used in experimental teratology, but a 
number of different routes of administration as well. Some protocols call for the daily 
administration of the teratogen over the entire course of the pregnancy (for example, 
Finnell 1981), and others for two or three (or more) administrations on consecutive 
days during the pregnancy (for example, Hanson and Hodes 1983). 
No single published protocol was found to be suitable, and an empirical approach was 
adopted to determine the optimal dosage. A toxicity study was done to establish the 
threshold of maternal toxicity. Daily administrations of 300 mg phenytoin per kg. body 
weight to non-pregnant females produced restless, aggressive behaviour, and 
because the animals were clearly under stress this regimen was not continued. When 
the daily dosage was reduced to 200 mg/kg phenytoin, no overt signs of toxicity 
resulted apart from a small decrease in weight (Table 3.1). The weight of control 
animals remained unchanged. The experiment was not continued beyond the sixth 
day due to increased resistance from the animals to intubation. 
7 4 
Table 3.1 
Adult mouse body weight after 6 consecutive daily administrations of 200 mg/kg 
phenytoin 
WEIGHT IN GRAMS 
Daya Day6 Change(g) 
22.69 20.92 -1.77 
20.34 19.71 -0.63 
21.17 20.15 -1.02 
20.08 19.15 -0.93 
21.92 20.39 -1.53 
21.36 21.34 -0.02 
21 .80 20.43 -1.37 
21.15 19.57 -1.58 
23.49 22.18 -1.31 
21.02 19.88 -1.14 
22.67 21.75 -0.92 
20.73 19.61 -1.12 
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It was judged that a dosage of 200 mg/kg, administered on one day rather than on six 
consecutive days, was likely to fall below the threshold of maternal toxicity and yet be 
high enough to produce a teratogenic outcome. 
3.2.2 Effects of Acute in vivo Phenytoin Exposure on Fetal Weight and Fetal Brain 
Weight 
Mean fetal weight of 181 / 2 day fetuses that had been exposed to phenytoin (200 
mg/kg) on gestational day 81 / 2 was significantly less (P < 0,01) than unexposed 
fetuses. There was also a significant decrease in fetal brain weight (P< 0,001). These 
findings are summarized in Table 3.2. 
There was likewise a significant reduction in the mean weight of 181 / 2 day fetuses that 
had been exposed to phenytoin (200 mg/kg) on day 91 / 2 (P < 0,02). Fetal brain 
weight, however, was not significantly reduced (see Table 3.3). 
These results are in accordance with the findings of earlier studies that dealt with the 
effects of phenytoin on the mouse fetus. For example, Harbison and Becker (1969) 
reported a statistically significant dose-related reduction in fetal body weight after 
single treatments of phenytoin on gestational days 9 to 15. Unexpectedly, Harbison 
and Becker found that on day 8 only the lowest of four dosages of phenytoin gave a 
significant result, while one day later, on day 9, the highest dosage resulted in the 
greatest weight reduction. 
Hanson and Hodes (1983) reported a significant reduction in the mean weight of 
mouse fetuses from the ICR, A/J, (B6A)F2 and c3H/He strains, after exposure to 75 
mg/kg of phenytoin on gestational days 10, 11 and 12, as compared to controls. 
Finnell (1981) also analysed the effects of phenytoin on the fetuses from a number of 
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different mouse strains, and found that fetal weights decreased significantly in all the 
strains as the dosage of phenytoin increased. 
Fritz and colleagues (1976), found a significant decrease in the mean fetal weight of 
MNRI fetuses after treatment with 100 mg/kg and 170 mg/kg phenytoin on gestational 
days 6 to 15. Gibson and Becker (1968) observed a significant reduction in fetal 
weight of Swiss-Webster and A/ J mice after phenytoin exposure (50 mg/kg) on 
gestational days 11, 12 and 13, but not on gestational days 7,8 and 9. It appears from 
the data supplied by Gibson and Becker that phenytoin is not teratogenic to either 
Swiss-Webster or A/J mice when administered during early embryogenesis (days 7, 8 
and 9). Only Sullivan and McElhatton (1977) found no significant difference in fetal 
weight between the phenytoin treated mice and untreated controls. 
These findings cannot be directly compared to the data on fetal weights presented 
Tables 3.2 and 3.3, due to both the differences in strain of mice used and also 
differences in methodolgy. Clearly, phenytoin induces fetal weight ,reduction under a 
diversity of experimental conditions. In terms of mechanism, the action of phenytoin 
in causing a decrease in fetal weight may be non-specific, and the decrease in weight 
may reflect an embryotoxic rather than a teratogenic manifestation. 
The statistically significant reduction in fetal brain weight after phenytoin exposure on 
day 81 I 2 is to be expected in view of the corresponding reduction in fetal body weight. 
The absence of a statistically significant reduction in brain weight of fetuses exposed 
to phenytoin on day 91 I 2 is difficult to explain in the light of a significant reduction in 
body weight, and there are no available literature reports on fetal brain weights after 
phenytoin exposure to put this finding into suitable context. 
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Table 3.2 Summary of results of Phenytoin Exposure at 200 mg/kg on 
Gestational Day s 1 / 2 
Test Control p 
(n=27) (n = 13) 
Total 38 18 ns 
conceptions 
Resorptions 5 3 ns 
Intra-uterine 3 1 ns 
deaths 
Abnormalities 3 1 ns 
2 anencephaly 1 exomphalos 
1 exomphalos 
Mean fetal weight 1,0472 1, 1347 p <0,001 
(g) (1 ,0044-1,0900) (1,0879-1 , 1815) 
Mean fetal brain 70,01 76,85 p < 0.001 
weight (68, 14; 71,88) (72,69; 81,01) 
(mg) 
(Figures in brackets are the 95% confidence interval for the population mean). 
ns = no significance 
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Table 3.3 Summary of results of Phenytoin Exposure at 200 mg/kg on 
Gestational Day 91 / 2 
Test Control p 
(n=22) (n = 14) 
Total conceptions 31 17 ns 
Resorptions 2 2 ns 
Intra-uterine 5 1 ns 
deaths 
Abnormalities 2 ns 
1 anencephaly 
1 exomphalos 
Mean Fetal 1,0350 1, 1031 p <0,02 
weight (0,9866;1,0834) (1,0510; 1,1552) 
(g) 
Mean fetal 71,86 74,85 ns 
brain weight (68,90; 7 4,82) (71,85; 77,85) 
(mg) 
(Figures in brackets are the 95% confidence intervals for the population mean) 
ns = no significance 
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3.2.3 Morphologic Abnormalities to the Fetus after in vivo Phenytoin Exposure 
In this study very few external anomalies were found (see Tables 3.2 and 3.3). There 
was no significant difference in the numbers of abnormalities between test and control 
animals. Anencephaly and exomphalos were the only abnormalities recorded in both 
treated and untreated mice. In literature reports the incidence of these abnormalities, 
and any other potentially lethal abnormalities, are extremely low. For example, Fritz 
and coworkers (1976), in an analysis of a total of 879 fetuses that had been exposed to 
phenytoin during gestation, recorded only one major malformation (spina bifida). 
Hanson and Hodes (1983) mentioned anencephaly, but did not give any incidence of 
frequency. Harbison and Becker (1969) obtained a 4% incidence of exencephaly in 
fetuses that had been exposed to a single dose of phenytoin (150 mg/ kg) on 
gestational day 9. 
In the present study no examples of cleft lip, cleft palate, open eyes or abnormal head 
shape were found. This is an unexpected result in view of the extensive reports of 
orofacial abnormalities in the literature. An explanation for this apparent discrepancy 
may be found in the protocols for drug administration used to obtain orofacial 
abnormalities. Harbison and Becker (1969) obtained orofacial abnormalities in fetuses 
that were exposed to phenytoin on days 11, 12, 13 and 14, which is considerably later 
than the time of phenytoin exposure in the present study. Harbison and Becker 
(1974) obtained an extremely high rate (85%) of orofacial anomalies after phenytoin 
exposure (at 87,5 mg/kg) on days 11, 12 and 13. On day 10, at almost double the 
dosage of phenytoin, the rate of orofacial anomalies was much less, and although the 
rate was still very high (42%), the corresponding resorption rate (67%) suggests that 
the dosage was excessive. Sullivan and McElhatton (1977) obtained a 5, 1% frequency 
of full-length cleft palate; their schedule of drug administration called for daily dosages 
of phenytoin on days 6 to 16, and conceivably the abnormal palates could have arisen 
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as a result of susceptibility to phenytoin teratogenicity during the latter half of the 
dosing period. Susceptibility to orofacial abnormalities appears to be strain related. 
For example, Hanson and Hodes (1983) administered phenytoin on each of 
gestational days 10, 11 and 12, but obtained only one orofacial abnormality out of 131 
c3H/He fetuses; the A/J and AB6F strains produced a high percentage of orofacial 
abnormalities. These findings were to some extent confirmed by Gibson and Becker 
(1968), who obtained a 15,2% incidence of cleft palate in Swiss-Webster mice, and a 
30,8% incidence of cleft palate in A/ J mice, when phenytoin was administered during 
late embryogenesis (gestational days 11 , 12 and 13). 
Visual examination of the fetuses revealed no limb abnormalities. Abnormal digits are 
frequently the result of in vivo phenytoin exposure, and abnormalities include 
ectrodactyly, syndactyly (Harbison and Becker, 1969), digital hypoplasia (Finnell, 
1981), and retarded ossification of the digits (Sullivan and McElhatton, 1977). The 
mouse fetus appears to be susceptible to digit abnormalities when phenytoin is 
administered in the mid-gestational period, since Harbison and Becker (1969) obtained 
a 9% frequency of ectrodactyly in the offspring of Swiss-Webster mice that were 
exposed to phenytoin on the ninth day of gestation. The absence of digital anomalies 
in the present study may be accounted for by the c3H strain being relatively resistant 
to this kind of injury. 
No morphologic abnormalities of the fetal brain were noticed. Harbison and Becker 
(1969) reported the symmetrical enlargement of the ventricles of the fetal mouse brain 
after a single administration of phenytoin (150 mg/kg) on the tenth day of gestation. 
This kind of abnormality, however, can only be detected by the preparation of ultrathin 
sections of brain tissue and their examination under a microscope. Similar techniques 
were presumably available to Finnell (1981), who reported immaturely developed 
cerebral ventricles in fetuses exposed to phenytoin, and also to Sullivan and 
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McElhatton (1977), who found enlarged cerebral ventricles after in vivo administration 
of phenytoin to fetal mice. 
3.2.4 Effect of in vivo Phenytoin Exposure on Resorption Rate and Rate of Intra-
uterine Death 
The rate of fetal mortality as a result of phenytoin exposure was not significantly 
different from the mortality rate among unexposed fetuses (see Tables 3.2 and 3.3). 
The implication is that phenytoin at 200 mg/kg is not potently embryotoxic, although 
the reduced fetal weight among exposed fetuses suggests that there is some degree 
of embryotoxicity. 
In most of the reports on the effects of teratogenic dosages of phenytoin on fetal mice, 
there is no increase in fetal mortality among treated fetuses, as compared to untreated 
fetuses. Gibson and Becker (1968) found that phenytoin at 50 mg/kg did not 
significantly increase the resorption rate in Swiss-Webster mice, although in a later 
study using a similar methodology, but a higher dosage of phenytoin (150 mg/kg), a 
significant difference in resorption rates between treated and untreated mice was 
obtained (Harbison and Becker, 1969). Sullivan and McElhatton (1977), using COi 
mice, found no significant difference in resorption rates in any of the phenytoin treated 
groups compared with controls. 
Some strains of mice, including the c3H/He strain used in this study, have a high 
resorption rate among the untreated animals. In this study the spontaneous resorption 
rate varied between 12% and 17%, while Hanson and Hodes (1983) report a rate of 
17% for c3H/He mice in this study. Sullivan and McElhatton (1977) gave a 11,8% rate 
of dead and resorbed fetuses among the untreated animals in the strain they used 
(COi). The A/ J strain also has a significant spontaneous resorption rate, although in 
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this strain phenytoin does have a significant effect on the resorption rate, with 
phenytoin administration on days 11, 12 and 13 producing a resorption rate of 35%, 
compared with 14,3% for untreated animals (Gibson and Becker, 1968). 
The resorption rate appears to be dependent on the route of phenytoin administration. 
Harbison and Becker (1969) found that a single intra-peritoneal injection of 150mg/ kg 
phenytoin on the tenth gestational day resulted in approximately 80% resorptions, 
while oral and subcutaneous administrations resulted in significantly fewer resorptions 
(no data given) . 
It is difficult to review the frequency of intrauterine deaths (as distinct from resorptions) 
due to ambiguities in the literature. Many studies do not distinguish between 
resorptions and intrauterine deaths. Fritz and coworkers (1975) usefully distinguished 
between embryonic resorptions (those deaths which they estimate to have occurred 
before day 14), and fetal resorptions (deaths after day 14). Gibson and Becker (1968) 
distinguished between resorptions occurring in early embryogenesis (drug 
administration on days 7, 8, 9) and resorptions occurring in late embryogenesis (drug 
administration on days 11, 12 and 13). Harbison and Becker (1969) administered 
phenytoin up to day 15, and included all deaths at laporotomy ( day 19) under 
"resorptions", while in the present study fetal deaths that occurred as early as day 12, 
were considered to be intrauterine deaths. 
3.2.5 Changes to the Protein Complement of Fetal Brain 
Although phenytoin-associated fetal weight reduction, resorptions, and morphological 
abnormalities, have been intensively investigated in mice, comparatively little is known 
about the molecular events that accompany these changes. Part of the aim of this 
study, therefore, was to analyse some of the molecular events that occur in fetal brain 
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after phenytoin exposure, with the view to obtaining some insight into the mechanism 
of action of phenytoin. 
Two-dimensional gel electrophoresis was chosen as a potentially suitable technique 
for approaching this task. The technique has the advantage of displaying a mixture of 
a large number of different proteins; drug effects on a particular tissue may produce 
alterations in the pattern of proteins, and these alterations may then become the 
starting point of an investigation into the nature and cause of the drug effect. Such an 
experimental approach was thought to be particularly advantageous to use on the 
brain, in view of the great difficulty otherwise of finding a starting point in so complex 
an organ. 
A representative two-dimensional polyacrylamide gel that was generated from fetal 
mouse brain and electrophoresed under the conditions described in Chapter Two is 
shown in Figure 3.1. The ordinate and the abscissa are marked for molecular weight 
and isoelectric point respectively. Only proteins in a molecular weight range 
approximately of 14 to 120 kd, and a limited pH range of 4,8 to 7,0, were separated. 
Up to 1250 proteins were discernible on a freshly stained gel. The actual gels 
measured approximately 20x24 cm; the photographs therefore represent a size 
reduction of about 15%. 
A number of changes were found in a comparison of brain protein patterns obtained 
from fetuses that had been exposed to phenytoin (200 mg/kg) on day a 1 I 2 and day 
91 I 2, and untreated controls. Five proteins in all underwent pronounced modifications, 
three of them in concentration, and two in position. These changes are significant 
because they appear to represent an explicit response by the fetal brain tissue to 
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The unequivocal changes are indicated and numbered on Figure 3.1 : 
Protein 1 (approximate molecular weight 80 kd, pl 4.9) . This protein is apparently 
absent from fetal brain tissue that had been exposed to phenytoin (see Figures 3.2 
and 3.3) . In fact, protein 1 was present in about 28% (7 out of 24) of gels that were 
generated from brain tissue of fetuses exposed to phenytoin at gestational day a 1 I 2; 
these gels displayed protein 1 at intermediate intensities. Fetuses exposed at day 
91 / 2 did not express this protein at all. 
Protein 2 (molecular weight 25 kd, pl 5.1) is absent from the control gels, but is 
present on all the gels derived from fetal brain tissue that had been exposed to 
phenytoin (see Figures 3.2 and 3.3). The spot of comparable intensity directly above 
protein 2 may be used as a yardstick to assess this unambiguous change. In Figure 
3.3 a vertical smear (representing an area of protein overloading) lies across protein 2, 
raising the possibility that protein 2 is an artifact of protein overloading. However, in 
Figure 3.2 protein 2 is clearly present without being bisected by the band of 
overloading. 
Protein 3 (molecular weight 55 kd, pl 5.3) was too faint to be detected by means of 
Coomassie staining. The absence of this protein spot from Figures 3.2 and 3.3 is not 
due to unsatisfactory staining, since the protein patterns on the gels represented by 
Figures 3.2 and 3.3 are in fact more intensely stained than in the control gel. 
Proteins 4 and 5 (molecular weight 35 kd, pl 6.0 and 6.1) show no change in 
concentration between gels derived from phenytoin treated animals, and gels derived 
from control animals. However, phenytoin administration on day 91 / 2 had the effect of 
shifting the pl of both these proteins towards a higher pH - a shift of approximately O, 1 
pH units. The molecular weight of proteins 4 and 5 remained unchanged on all the 
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gels. The fuzziness of these two spots in Figure 3.3 was not present on other 
equivalent gels. The possibility was considered that protein 5 did not undergo a shift 
in position, but that protein 4 had a shift of 0,2 pH units, taking it to the other side of 
protein 5. However, it is thought more likely that both proteins had a positional shift, 
because protein 5 has a slightly smaller molecular weight than protein 4, and the 
pattern of the left spot being slightly further down (in Figure 3.2) is preserved in Figure 
3.3. 
All other differences noticeable between Figures 3.1, 3.2 and 3.3 were not consistently 
present in the other equivalent gels, and the presence of these other, variable, 
differences was attributed to non-uniformities in the staining process, and also to non-
uniformities in the casting and running of the gels. The difficulties in achieving 
reproducibility hampered any investigation of subtle quantitative differences between 
proteins. 
None of the five proteins of interest has been identified. It is impossible at this stage 
to say to which classes of proteins they belong (enzymes, glycoproteins, structural 
proteins etc), or to assign them to subcellular fractions. Knowing this, and knowing 
their relationship to one another, is likely to go a long way towards establishing their 
intracellular function, and their role in the modulation by phenytoin of protein 
expression. 
The mechanism responsible for the elevation or reduction in the concentration of these 
proteins (or the shift in position) cannot be deduced without knowing more about 
them. The complete absence of protein 1 from fetal brain tissue after phenytoin 
exposure on day 91 / 2 is presumably due to the inhibition of its expression. That 
inhibition could have occurred at the level of the gene, during the translation of RNA 
into protein, or during post-translational processing. The agent responsible for the 
inhibition may have been phenytoin, a metabolite of phenytoin, or it may have followed 
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on from another, more primary event induced by phenytoin. The apparent inhibition of 
protein 3 may have occurred by a similar mechanism. 
The presence of protein 1 in 7 out of 24 samples obtained from fetuses exposed to 
phenytoin on day 81 / 2 presents additional questions. The total absence of this protein 
one day later in gestation suggests that this inhibition may be developmentally 
regulated, a suggestion that can be verified by exposing the fetus to phenytoin on day 
71 I 2, and also on days following day 9
1 I 2· 
That there is also an apparent induction of a brain protein (protein 2) as a result of 
exposing the fetus to phenytoin, suggests that the intracellular actions of phenytoin 
are diverse and complex. The types of cells in which these deletions and deductions 
occurred are not necessarily the same, and in view of the great cellular variety in the 
brain, it is unlikely that they are the same. Protein 2 may conceivably be one of the 
drug metabolizing enzymes, although not cytochrome P-450, which, although it is 
present in the mouse brain and is susceptible to induction by phenytoin (Volk et al., 
1988), has a moderately basic pl (Vlasuk and Walz, 1980), which is incompatible with 
the pl of 5, 1 of protein 2. The induction of protein 2 is unlikely to be due to gene 
amplifications, since gene amplification is normally the result of chronic drug treatment. 
Nor is protein 2 likely to be one of the so-called "heat shock" proteins, since they are 
synthesized in minute quantities. Establishing the functional characteristics of this 
protein is likely to cast new light on the way in which phenytoin modulates cellular 
function. However, it may be that these protein changes are merely the more 
conspicuous features of widespread cellular perturbations, and that the primary 
actions of phenytoin may continue to remain occluded by the intricacies of cellular 
biology. 
Phenytoin administration on gestational day 91 / 2 (but not day 8
1 / 2) produced a shift in 
the isoelectric points of proteins 4 and 5. Both proteins underwent the same shift in 
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pl, suggesting that phenytoin induced the same quantitative modification to both 
proteins. The fact that proteins 4 and 5 have similar molecular weights, and have pis 
so close together, plus the observation that phenytoin appears to produce a near 
identical shift in the pl of both proteins, suggests that these proteins may be 
structurally closely related. If this is so then any phenytoin-induced change would 
affect both proteins equally. It is possible that proteins 4 and 5 are so similar because 
they were originally the same protein, and that during the sample solubilization 
process they were subjected to modifications. If roughly 50% of the protein molecules 
were modified (for instance, by the removal of a charged side-chain) , then the 
molecular weight would remain virtually unchanged, but there would be a significant 
difference in pl. Another possibility is that proteins 4 and 5 are the products of two 
genes that diverged very recently in evolutionary terms. 
Phenytoin is recognized as having widespread protein modulatory effects in the brain 
and in other organs. Hicks and coworkers (1983) reported that in the primary palates 
of phenytoin-treated embryos, DNA synthesis was decreased and protein synthesis 
was increased by 2,2 times, compared with control primary palates. A general effect 
such as this may presumably account for the reduction in fetal body weight and brain 
weight found in this study. Numerous reports have dealt with the effects of phenytoin 
on protein synthesis in mature animals. Yanagihara and Hamberger (1971) found 
that phenytoin inhibited the incorporation of tritiated leucine into proteins in the 
cerebral cortex of the rat. A more recent report dealt with the phenytoin-associated 
decrease in the phosphorylation level of (Na+, K+)- ATPase in mouse brain (Guillaume 
et al., 1983). In rats exposed to high dosages of phenytoin, histologically detectable 
changes and degenerative changes in the cerebellum have been reported (Kokenge 
et al., 1965). 
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Because of these diverse and widespread effects of phenytoin, it is important to ask if 
the protein changes reported in this study are necessarily teratogenic manifestations. 
Teratogenic effects, by definition, result in gross or subtle abnormalities close to or at 
birth. While the present protein changes are evidently not part of the developmental 
programme of the fetal mouse brain, they should not for that reason be labelled 
abnormal, and there is no evidence that the fetuses are at any disadvantage for having 
a different protein complement. The protein changes induced by phenytoin in this 
study appear to be uniform and general, in that they were experienced by all the 
fetuses to the same extent (except for protein 1). Phenytoin-related teratogenic 
effects, however, seem randomly to affect some fetuses in a litter, but not others (at 
dosages which give a moderate resorption rate). It seems, therefore, that it cannot be 
taken for granted that we have a teratogenic effect, and that alternative hypotheses 
must be considered: 
(a) A developmental toxic manifestation. The modified protein expression is 
possibly the result of a toxic insult by phenytoin on certain target cells within the 
developing brain, without concomitant necrosis or a grossly modified developmental 
programme. This hypothesis is supported, in the present study, by a significant 
reduction in fetal weight, without a significant increase in the resorption or 
malformation rate. The induction and deletion of specific proteins may be due to a 
cellular "stress response", a hypothetical homeostatic mechanism whereby the tissue 
produces new proteins and eliminates others in order to minimize the toxic effects of 
the drug. 
(b) A "pre-teratogenic" manifestation. The altered protein pattern may represent 
one of the inceptive steps in the complex process that eventually results in a full-blown 
teratogenic manifestation. This postulate arises out of the apparent contradiction of 
having phenytoin-induced molecular changes that are universal (occurs in every 
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fetus), while the reported pattern of phenytoin-induced morphological abnormalities is 
random (affects some fetuses in the litter, but not others). In this scenario, the early 
step is not sufficient to produce a teratogenic outcome, and must be succeeded by 
one or more additional steps before the fetus suffers a developmental aberration. 
Increasing the dosage of phenytoin (in this case, beyond 200 mg/kg) may increase the 
likelihood of subsequent steps taking place. Genetic factors in individual fetuses may 
determine why, at a given dosage of phenytoin, some fetuses pass through the 
hypothetical multistep process leading to morphological defects, while others do not. 
(c) The altered proteins have no developmental role. This hypothesis proposes 
that changes to the protein complement may occur in a variety of fetal and adult 
tissues after exposure to phenytoin. This may be a general response to a particular 
environmental insult, and the mechanism of this hypothetical response can be 
expected to be quite different from the mechanism responsible for phenytoin 
teratogenicity. The phenytoin-induced dephosphorylation of (Na+ , K + )-ATPase in 
adult mouse brain (Guillaume et al., 1986) may, for example, also take place in fetal 
mouse brain without producing a developmental outcome. This hypothesis can easily 
be tested by examining the protein patterns obtained from various tissues, both fetal 
and adult, of phenytoin-exposed animals. The fact that these protein changes are 
present 1 O days after the insult argues against this hypothesis, because there was 
likely to have been adequate time for repair to occur. 
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3.3 Conclusions 
In this study phenytoin at 200 mg/kg produced a significant reduction in fetal weight 
and brain weight when exposure occurred on gestational day s 1 / 2, and a significant 
reduction in fetal weight only when exposure took place on day 9
1 I 2. 
No significant increase in the rate of resorptions or of abnormalities was found. 
Two-dimensional gel electrophoresis of total brain proteins revealed a phenytoin-
associated change in the protein pattern; alterations included two deletions, an 
induction and two changes in pl. The proteins that underwent modulation could not be 
identified, and their function could not be determined. 
To my knowledge, this is the first teratological study in which two-dimensional gel 
electrophoresis was used to show protein changes induced in the fetal mouse brain 
by phenytoin. However, the protein changes are not necessarily teratogenic 
manifestations, because it cannot be assumed that they are associated with injury to 
the fetal brain. The changes can only be characterized as teratogenic once they have 
been correlated with histological, morphological or behavioural abnormalities. 
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CHAPTER 4 
EFFECTS OF IN VIVO DISULFIRAM EXPOSURE ON FETAL MOUSE BRAIN WEIGHT 
AND BRAIN PROTEIN COMPLEMENT 
4.1 Introduction 
4.1.1 Pharmacological Properties of Disulfiram 
Disulfiram has been used for years in the treatment of chronic alcoholism. The drug is 
thought to act through the inhibition of aldehyde dehydrogenase and alcohol 
dehydrogenase (Carper et al., 1987). The failure by a person to abstain from ethanol 
intake while under treatment with disulfiram results in a rise in serum acetaldehyde, 
leading to a wide variety of unpleasant systemic effects, including nausea, vomiting, 
headache, sweating and thirst. The enhancement of the adverse effects of ethanol is 
therefore the basis of disulfiram aversion therapy. However, the use of disulfiram as a 
therapeutic agent has been curtailed in recent years because the concomitant 
ingestion of disulfiram and ethanol by sensitive individuals may result in severe cardiac 
effects, convulsions, and death (Goodman and Gilman, 1985). 
Disulfiram, when taken by itself, is relatively nontoxic. Minor side-effects include 
drowsiness, headache, memory impairment, decreased libido, gastro-intestinal 
symptoms, halitosis, and skin rashes (Bradley and Hewer, 1966). Kump and 
colleagues (1979) reported a disulfiram-induced acute organic brain syndrome that 
was reversed after discontinuance of the drug. Cases of peripheral neuropathy in 
persons on long-term disulfiram therapy have been reported by Bradley and Hewer 
(1966), and Watson (1980). Histological investigations on material obtained from 
nerve biopsies by Watson (1980), revealed dissolution of axoplasmic organelles as 
well as collapsed and distorted myelin sheaths. All of the patients examined by 
1 00 
Watson had stopped taking alcohol before the onset of disulfiram-associated 
symptoms, making the possibility of an alcohol-associated neuropathy improbable. 
4.1.2 Is Disulfiram a Central Nervous System Teratogen? 
Case reports suggest that disulfiram has some teratogenic potential. For example, 
Nora and co-workers (1977) reported on two infants with severe limb reduction and 
other skeletal anomalies, whose mothers had been maintained on a disulfiram sobriety 
regimen during the first trimester of pregnancy. A prospective cohort of five human 
pregnancies in which there was maternal exposure to disulfiram revealed one 
spontaneous abortion, two infants with clubfeet and two normal infants (see Nora et 
al. , 1977). Gardner and Clarkson (1981) gave a single case report of a severely 
malformed and retarded child whose previously alcoholic mother had taken disulfiram 
early during pregnancy. 
Animal experimentation suggests that disulfiram has embryotoxic potential. Salgo and 
Oster (197 4) were able to obtain a fetal resorption rate of 83% in rats on the twelfth day 
of pregnancy; reproductive failure was attributed to the copper-chelating activity of 
disulfiram. Thompson and Falb (1985) found that the in vivo administration of high 
dosages of disulfiram to mice resulted in a significant increase in early resorptions. 
An in vitro mouse embryo culture system revealed that disulfiram has widespread 
morphological and histological effects on 8-day mouse embryos; among the organs 
affected was the central nervous system (Thompson and Folb, 1985). 
The possibility therefore exists that disulfiram does have teratogenic potential, and the 
aim of this study was partly to seek preliminary data in support of this possibility, using 
the methodology described in Chapter 2. 
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4.1.3 Effects of Disulfiram on Protein Expression: Literature Reports. 
The ability of the major metabolite of disulfiram to chelate heavy metals has 
widespread enzyme effects. Several metalloenzymes, including alcohol 
dehydrogenase, aldehyde dehydrogenase, and dopamine beta-hydroxylase, are 
inhibited as a result of the chelating of copper and other heavy metals by the principal 
metabolite of disulfiram, diethyldithiolcarbamate (Levinson et al. , 1978). The malaria 
parasite, Plasmodium is particularly rich in cytochrome oxidase, a metalloenzyme, and 
disulfiram has been effectively used as an in vitro anti-malarial agent (Scheibe! et al. , 
1979). Disulfiram has also been shown to have anti-viral activity in vitro, by the 
inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus, which is a 
metalloenzyme (Levinson et al. , 1978). 
Disulfiram is also an ionophore of copper. Hannan and McAuslan (1982) have 
postulated that treatment with disulfiram may achieve more efficient localization of 
metal ions at the target, than treatment with metal salts, at a given concentration. 
The drug has also a marked general effect on the synthesis and expression of both 
cellular and secretory proteins. For example, Hannan and co-workers (1982) fou'nd 
that disulfiram caused a 50 to 70% inhibition of the total incorporation of 
35s-
methionine into clonal cell lines of vascular endothelial cells. Over and above this 
general suppression of protein synthesis, there was also the total inhibition of specific 
secretory proteins, for example fibronectin and collagen (Hannan et al., 1982). This 
inhibition was both rapid (within 30 minutes) and irreversible (still effective after 24 
hours). Two hybridoma cell lines treated in a similar way failed to produce lgM and 
lgG chains (Hannan et al., 1982). 
The mechanism responsible for the general inhibition of protein synthesis by disulfiram 
is unknown. A possible explanation is that disulfiram has this effect on protein 
expression because the drug inhibits the copper-dependent enzyme responsible for 
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peptide amidation (Mains et al., 1986). Peptide amidation, which involves the 
conversion of peptides terminating in -x-gly to amidated peptides terminating in -x-NH2 
is an essential process during protein biosynthesis, and any alterations in the levels of 
amidated peptides may be expected to have wide-ranging effects. The effect of 
disulfiram on specific secretory proteins is postulated by Hannan and co-workers 
(1982) to result from its role as an ionophore; other ionophores also act as selective 
inhibitors of the expression of extracellular proteins. 
Diethyldithiolcarbamate, the major metabolite of disulfiram, has the ability to act as a 
mercaptan, and therefore may inhibit enzymes with sulfhydryl groups (Mains et al. , 
1986; Goodman and Gilman, 1985). It appears, therefore, that there are a number of 
different ways by which disulfiram may induce changes to protein expression. The 
inhibition of peptide amidation occurs in the rat at dosages of disulfiram similar to the 
human therapeutic dosages (Mains et al., 1986), and the disulfiram-associated protein 
modulatory effects may well account for some of the side-effects that result from long-
term disulfiram use. It seems reasonable to suppose that some or all of these protein-
modulatory effects may also occur in fetal tissues, and if so, two-dimensional gel 
electrophoresis may be an appropriate technique for detecting such manifestations in 
fetal mouse brain. 
4.1.4 Disulfiram and the Heat-Shock Proteins 
In addition to the abovementioned protein modulatory effects apparently mediated by 
disulfiram, the drug also appears to be capable of inducing the synthesis of the so-
called heat-shock proteins. These proteins first became th~ subject of study when it 
was noticed that transient hyperthermia induced the same set of proteins (or a very 
similar set) in a wide variety of animal and plant tissues. Subsequently it was 
discovered that the heat-shock response may be evoked by a diversity of 
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environmental agents, including toxic substances, a number of therapeutic agents, 
and some teratogens (see Schlesinger et al. , 1982). 
Although the evidence is still indirect, disulfiram appears to be capable of inducing the 
synthesis of the heat-shock proteins. Levinson and co-workers (1978) reported that 
disulfiram induced the synthesis of four proteins, of approximately 100 kd, 70 kd, 35 kd 
and 25 kd, in chick embryo and human foreskin cells; Hannan and McAuslan (1982) , 
using bovine endothelial cells, found that disulfiram induced a similar set of proteins, of 
83 kd, 73 kd, 32 kd and 28 kd. The predominant heat-shock protein found in other 
tissues is the 70 kd species, while heat-shock proteins of 22-27 kd and 80-90 kd are 
found in virtually every species (Schlesinger et al. , 1982). Significantly, Johnston and 
colleagues (1980) reported that four proteins induced by disulfiram in chick fibroblasts 
were the same as those induced by sodium arsenite, and that the latter co-migrated 
with heat-shock proteins expressed in the same tissue. 
The heat-shock response has been reported to occur in a great variety of tissues, 
including brain, thymus, heart, lung, spleen, liver, and kidney (Currie and White, 1981). 
Tissues of the developing organism also appear to be susceptible to the heat-shock 
response; this has been shown in Drosophila and Xenopus, and in cultured 
mammalian cells (mouse embryonal carcinoma stem cells from brain and nervous 
tissue), as well as the rat fetus at mid-gestation (Walsh et al. , 1987). German (1984) 
demonstrated that heat-shock manifestations occurred in the 12-day-old mouse 
embryo. It was therefore decided to determine whether disulfiram induces the 
synthesis of heat-shock proteins in the fetal mouse brain, since such a finding could 
conceivably be relevant to an investigation of the potential teratogenic manifestations 
of disulfiram. 
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4.2 Drug administration 
A suitable dosage of disulfiram was difficult to establish because so few teratogenic 
investigations have been reported. Salgo and Oster (1974) administered disulfiram to 
rats at 100 mg per animal continuously over a number of days during pregnancy. This 
dosage protocol was not considered to be suitable for the present study because of 
the extremely high dosages used (approximately 2 g/kg), and also because an acute 
exposure was required to coincide with a specific stage in the development of the 
mouse brain. The protocol of Thompson and Falb (1985) could also not be used, 
because the animals were exposed to disulfiram for the duration of pregnancy 
It was therefore attempted to estimate an adequate teratogenic dosage by using the 
toxic dosage (in the adult animal) as a guideline. Salgo and Oster (1974) described 
the toxic manifestations in adult rats after chronic exposure to high dosages of 
disulfiram. Similar manifestations were not observed in the present study after the 
acute exposure of c3H mice to disulfiram, and single dosages of up to 1,5g/kg 
appeared to have no untoward effects. Additional criteria were therefore considered 
to establish guidelines for the selection of a teratogenic dosage. In view of the 
widespread disulfiram-associated protein effects, sodium dodecyl sulphate 
polyacrylamide gel electrophoresis was performed on homogenized adult mouse 
brain at various intervals after drug administration. An unknown brain protein of 
approximately 25 kd was induced, and first became discernible following the ingestion 
by mice of 450 mg disulfiram per kg; the effect appeared to be dose related and 600 
mg/kg had a marked effect. Since this effect was possibly a toxic manifestation, the 
higher dosages were not considered for teratogenic investigations. Pettersson and 
Tottmar (1982) had found that single dosages of 300 mg disulfiram/kg resulted in 
enzyme inhibition in rat brain and liver. In view of the above findings it was decided 
that disulfiram at 450 mg/kg was potentially an adequate teratogenic dosage. 
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Drug administration was by means of gastric intubation. Disulfiram is insoluble in 
water and only sparingly soluble in alcohol; Pettersson and Tottmar (1982) 
administered the drug as a suspension in 5% gum arabicum. In the present study 
disulfiram was administered as a partial suspension in arachis oil, because arachis oil 
had been used previously and found to be acceptable to mice (Pillans et al. , 1988). A 
maximum volume of 100 µI was administered and none of the mice showed any ill-
effects. Controls received arachis oil only. 
In order to expose the fetus to disulfiram during critical stages of central nervous 
system development, the drug was administered as single dosages on either 
gestational day 81 / 2 or 9
1 / 2, as in the phenytoin study. 
4.3 Effects of in vivo disulfiram exposure on fetal weight and fetal brain weight 
Disulfiram (450 mg/kg), when administrated to pregnant mice on day 8
1 / 2 post 
conception, had no significantly effect on fetal weight at day 18
1 / 2; there was, 
however a significant increase in fetal brain weight (p<0,05). There were no 
significant differences in the occurrence of resorptions, intra-uterine deaths, or 
macroscopic abnormalities between test and control fetuses. 
When the same dosage of disulfiram was administered on gestational day 9
1 / 2, there 
was a significant increase in fetal body weight (p < 0,05), but not in _fetal brain weight of 
test animals. This result was unexpected in view of the findings by Salgo and Oster 
(1974), namely, that disulfiram caused a significant reduction in fetal weight. (See 
Tables 4.1 and 4.2). 
The results of Salgo and Oster (1974), how~ver, were obtained with dosages that were 
toxic to the dams. At much lower dosages of disulfiram, administered for the duration 
of pregnancy, Thompson and Falb (1985) found no significant reduction in fetal weight. 
No explanation can be offered for the increase in body weight of fetuses exposed to 
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Table 4.1 Summary of the effects on fetal c3H mice after in vivo exposure to 450 
mg/kg disulfiram on gestational day s 1 / 2 
Test Control p 
(n=14) (n= 10) 
Total conceptions 18 13 
Resorptions 1 1 ns 
Intra-uterine deaths 2 1 ns 
Abnormalities 1 1 ns 
exomphalos exomphalos 
Mean fetal 1, 1761 1,1313 ns 
weight (g) (1, 1338-1,2184) (1,0458-1,2168) 
Mean fetal 78,76 74,60 p<0,05 
brain weight (mg) (76,08-81,44) (72,07-77, 13) 
(Figures in brackets are the 95% confidence intervals for the population mean) 
ns = no significance 
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Table 4.2 Summary of the effects on fetal c3H mice after in vivo exposure to 450 
mg/kg disulfiram on gestational day 91 / 2 
Test Control p 
(n=20) (n=12) 
Total conceptions 26 15 
Resorptions 2 1 ns 
Intra-uterine deaths 2 1 ns 
Abnormalities 2 1 ns 
exomphalos monster 
Mean fetal 1, 1048 1,0336 p<0,05 
weight (g) (1,0733-1, 1363) (0,9757-1,0915) 
Mean fetal 75,55 72,83 
brain weight (mg) (74,46-76,64) (69,31-76,35) 
(Figures in brackets are the 95% confidence intervals for the population mean). 
ns = no significance 
ns 
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disulfiram on day 91 / 2 of gestation or for the increase in fetal bra
in weight of fetuses 
exposed on day s 1 / 2, and this kind of finding is not generally associated with fetal 
drug exposure. 
There were no significant differences in the incidence of resorptions, intra-uterine 
deaths, or macroscopic abnormalities among fetuses exposed to disulfiram on 
gestational day 91 I 2, compared with controls (see Table 4.2). Both Salgo and Oster 
(1974), and Thompson and Falb (1985) found a significant increase in fetal resorptions 
after continuous disulfiram administration during gestation. It appears from the 
findings of this study that the mouse fetus is not susceptible to acute exposure to 
disulfiram at days s 1 / 2 and 91 I 2, at the dosage used. Thompson and Falb (1985) 
proposed that disulfiram does in fact have teratogenic potential, and further research 
may be required to establish at what stage of gestation, and at what dosages, the fetal 
mouse central nervous system is susceptible to disulfiram teratogenesis. 
4.4 Effects of disulfiram on the protein complement of fetal mouse brain 
No consistent disulfiram-associated changes were found in the fetal mouse brain 
protein complement. An analysis of the two-dimensional gel electrophoretic patterns 
obtained from disulfiram-exposed fetuses (gestational day 9
1 I 2) revealed an apparent 
protein induction (MW 90 kd; pl 5.2). However, this apparent change was present in 
only four out of 16 gels and was therefore regarded with scepticism, particularly in 
view of the fact that it occurred in an area of local protein overloading. 
The apparent absence of any disulfiram-induced changes is unexpected in view of the 
wide-ranging protein changes with which disulfiram is associated in adult tissues. 
Changes may in fact have occurred in the fetus immediately after drug administration, 
and these changes may then have been reversed by an as yet unknown fetal repair 
mechanism. 
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Another possibility is that the dosage of disulfiram used was in fact not adequate to 
give rise to a teratogenic (or other) effect. It is noteworthy that the protein modulation 
induced by disulfiram in the adult mouse brain (see section 4.2) was absent from the 
two-dimensional gels of fetal brain proteins. 
Among the protein changes that were anticipated but not found , were those 
associated with the heat-shock response. These proteins have acidic pis (between 5 
and 6) and molecular weights between 24 kd and approximately 100 kd, and they may 
therefore be expected to resolve within the parameters of the electrophoretic system 
that was used. Although the heat-shock proteins are minor components (even after 
induction) of the tissue protein complement, the higher molecular weight species 
(particularly the 70 kd protein) may readily be visualized on silver-stained two-
dimensional gels. Even careful scrutiny, however, revealed no protein modifications 
in those regions of the gels where the heat-shock proteins were most likely to be 
found. 
This inability to detect the heat-shock proteins cannot be taken as conclusive evidence 
that disulfiram does not induce the heat-shock response, and indeed, it would be 
highly significant if it was found that the heat-shock proteins are not inducible in fetal 
mouse brain. It is known that the expression of the heat-shock proteins is transitory, 
and adequate allowance should be made for the kinetics of heat-shock protein 
induction. Since the low-molecular weight heat-shock proteins are expressed in low 
copy number, labelling by means of the metabolic incorporation of radioactive amino 
acids may greatly increase sensitivity, as well as enhancing visualisation by limiting the 
number of protein spots displayed to only the newly synthesized proteins. 
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4.5 Disulfiram and the embryonic stress hypothesis of teratogenesis 
James German (1984) proposed that the induction of the heat-shock response in the 
mammalian embryo provides a common pathway by which diverse environmental 
agents may lead to developmental abnormalities. This hypothesis has profound 
implications for teratogenesis, and it will therefore be examined here, within the context 
of a discussion of the effects of disulfiram on the fetus. 
German proposed that the induction of the heat-shock proteins pre-empts the normal 
schedule of protein synthesis during development. The established program of 
activation and inactivation of genetic loci, essential for normal intra-uterine 
development, is therefore altered, leading to developmental abnormalities. German 
suggested that the precise period during gestation when the response is induced may 
determine the nature of the abnormalities. 
German's hypothesis flows from the long-established idea that fever during pregnancy 
may interfere with normal human embryonic development. Previously it was assumed 
that transient hyperthermia resulted either in outright cell death or a disruption of 
mitosis or cellular migration (see German, 1984). Transient hyperthermia was also 
found, however, to stimulate the heat-shock response. Other environmental agents, 
some of them teratogens, were likewise observed to stimulate the heat-shock 
response. The possibility therefore exists that the heat-shock response itself is 
responsible for the disruption to embryonic development, and indeed, it may be the 
common pathway whereby a variety of environmental agents induce fetal injury. 
German unfortunately presents no evidence to back up his hypothesis, and he also 
ignores some contradictions. For example, he fails to explain why sodium salicylate, 
which is not generally considered to be teratogenic, induces the expression of the 
heat-shock proteins. Although he notes that thalidomide does not elicit the heat-
111 
shock response, German does not explain why this powerful human teratogen should 
not share the common pathway with other known or suspected teratogens. 
German also fails satisfactorily to refute an alternative hypothesis for the biological role 
of the heat-shock response. Ashburner and Bonner (1979) formulated the idea that 
the expression of the heat-shock proteins may serve a protective role. Evidence 
from many studies has suggested that the threshold to injury, when a tissue is 
exposed to harmful environmental agents, is increased once the heat-shock response 
has been evoked, enabling the tissue to tolerate concentrations of toxins that may 
otherwise be lethal (see Schlesinger et al., 1984). This putative homeostatic role of 
the heat-shock response has received widespread support, and recent studies have 
revealed some of the molecular details of how these proteins may exercise a 
protective function (see, for example, Deshaies et al., 1988). 
The second hypothesis is particularly attractive because it is open to being tested. 
Little research has been done on the protective heat-shock response to drugs in the 
fetus. Disulfiram may be especially suitable in this role, since it appears to have 
teratogenic potential, and it is also suspected of being an inducer of the heat-shock 
response. A low dosage of disulfiram may well stimulate the protective response in 
fetal tissues, which may then prevent manifestations associated with toxic or 
teratogenic dosages of disulfiram. 
As for German's "common pathway" hypothesis, it seems more likely that there are 
diverse mechanisms whereby drugs, and xenobiotics, may cause injury to the fetus. 
Rather than seeking a single all-embracing mechanism, it may ultimately be more 
productive to concentrate on the mode of action of individual teratogens, and in this 
way establish how teratogens resemble one another, or differ from one another, in 
their mechanisms of action. 
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CHAPTER 5 
EVALUATION AND FUTURE PROPOSALS 
5.1 Two-dimensional Polyacrylamide Gel Electrophoresis 
Two-dimensional polyacrylamide gel electrophoresis is a powerful analytical technique 
that has been used by a number of researchers to evaluate the effects of xenobiotics on 
the protein complement of several different cells and tissues. In teratological research 
the technique has not been extensively used, and part of the aim of the present study 
was to explore the potential of two-dimensional gel electrophoresis for uncovering some 
of the molecular events that accompany the disruption of development by drugs. 
Approximately 1250 different proteins were detected by the electrophoretic system and 
staining procedure used in the present study. Using much larger, so-called "giant" gels, 
Young (1984) was able to detect approximately 3000 different proteins from rat thymus 
cells; an additional 2000 proteins were resolved from the same tissue when non-
equilibrium gels were also used. Klose and Zeindl (1984) resolved concentrated 
subcellular fractions on "giant" two-dimensional gels, and after multiple autoradiographic 
exposures (to detect proteins of extremely low copy number) they succeeded in 
detecting ~pproximately 1 O 000 different proteins from a single cell type. 
Although the development of "giant" gels represents a significant advance in the 
capability of the technique, these enormous gels are difficult to prepare and manipulate 
(Young, 1984). The gels used in the present study were approximately twice the area of 
the "standard" O'Farrell gel (O'Farrell, 1975), and produced a level of detection 
intermediate between the "standard" and the "giant" gels, without introducing the 
daunting technical difficulties associated with the latter. In the present study some 
attention was given to the statistical evaluation of differences between test and control 
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fetuses , and the task of running a complex "giant" gel on each specimen, and the 
examination of thousands of minor spots would therefore have been overwhelming. 
Nevertheless, the decision not to use the extremely large gels may have resulted in 
some drug-induced modulations of minor components remaining undetected. 
The formulation of the iso-electric focussing dimension dictated which sub-set of the total 
proteins was incorporated for electrophoretic analysis. For instance, the pH range 
employed in this study (pH 4.8 - 7.0) was chosen for the inclusion of the largest number 
of proteins combined with high-quality resolution, and ease of operation (see O'Farrell , 
1975). This range does not extend above pH 7 because the basic proteins resolve 
poorly on equilibrium (or steady-state) gels, and separate non-equilibrium 
electrophoresis is required for their resolution (see Young, 1984). The recent 
development of "immobilized" pH gradients has made iso-electric separation possible 
over an extended range (Hanash and Strahler, 1989). 
Streaking can result in a large increase in spot size, which makes the evaluation of 
quantitative changes difficult or impossible (O'Farrell, 1975). Some streaks may in fact 
consist of multiple spots that are poorly resolved, and these may in turn mask other, 
more indistinct, spots. In the present study (see Figure 3.1) streaking at the basic end 
of the gels could not be eliminated, and the analysis of the gels must therefore have 
been biased towards the detection of protein changes among the more acidic proteins. 
5.2 The Nature of the Protein Modifications 
The phenytoin-associated protein modulations reported in Chapter 3 appear to be 
largely unambiguous, with only one protein spot (spot 1 in Figure 3.1) present 
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intermediate concentrations. The apparent induction, deletions and changes in pl 
represent the full spectrum of protein modulatory manifestations detectable on two-
dimensional gels, and suggests that phenytoin may have wide-ranging biological 
effects in the fetal mouse brain. 
The fetal brains that were analysed electrophoretically were all macroscopically 
normal, and there is no evidence that the phenytoin-induced protein changes reported 
here are teratogenic manifestations. A correlation will have to be made between 
morphological or histological abnormalities and protein changes before the latter may 
be described as teratogenic. It is not obvious how the present study may be 
expanded to establish such a correlation, since the brain samples were solubilized 
immediately after removal from the fetuses. If only a portion of the brain is solubilized 
for electrophoresis, then the remainder may be used for other investigations, but the 
division of the sample will have to be made with a high degree of consistency if the 
protein patterns between samples are to be reproducible. Gel electrophoresis may be 
used to determine to what extent the two hemispheres of the fetal brain are 
homologous. If there is a high degree of homology then it may be possible to do an 
electrophoretic analysis on the one hemisphere, and morphological and histological 
examinations on the other; the assumption would be that drug-induced lesions in one 
hemisphere may be mirrored in the other. Behavioural studies may be conducted to 
clarify whether the phenytoin-induced brain protein changes are evidence of 
teratogenic impairment. Mice exposed to phenytoin at 200 mg/kg may well have 
learning or developmental deficiencies after birth, but it would still be necessary to 
establish a direct link between these deficits and anomalies in brain protein 
complement. The teratogenicity or otherwise of the phenytoin-induced protein 
changes is an important question and to solve it an experimental approach altogether 
different from the present one may be required. 
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It is possible that teratological damage, as evinced in histological or morphological 
anomalies, may not be conclusively reflected in correspondingly disrupted protein 
patterns. Klose and Putz (1983) found that gross chromosomal abnormalities 
(trisomies) in embryonic mice were accompanied by unexpectedly few protein 
changes. The implication of their work is that cells have powerful protein synthesis 
regulatory mechanisms, and if so, there is every reason to suppose that analogous 
homeostatic mechanisms may come into play during drug-induced injury to the fetus. 
The phenytoin-induced changes could conceivably be a generalised response by fetal 
tissue to exposure to high levels of xenobiotics, although the apparent absence of 
similar disulfiram-induced changes argues against this suggestion. The phenytoin-
associated protein changes need not even be fetus-specific, and all or some of the 
changes may also occur in the adult mouse brain after phenytoin administration. If 
such a phenytoin-associated response does occur in adult brain tissue, it may be 
related to the drug's anticonvulsant properties, or to one of the diverse and complex 
biological effects that phenytoin is known to have (see Chapter 3) . 
These difficulties in establishing the significance of protein changes are found to a 
greater or lesser extent in other studies that are heavily reliant on two-dimensional gel 
electrophoresis. For example, Anderson and co-workers (1986) found that no less 
than 31 proteins from mouse liver showed quantitative differences following exposure 
to chlorinated hydrocarbons. The aim of their study was to establish the mechanism 
of toxicity of chlorinated hydrocarbons, but the realization of this aim will entail the 
determination of the identity and function of the majority of the modulated proteins, and 
even after the completion of this formidable task the mechanism may still remain 
elusive. Marshall and co-workers (1985) found that dimethylformamide induced minor 
but reproducible protein changes in rat serum. The aim of the study was largely 
technical (a comparison of two-dimensional electrophoretic methods) and the authors 
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included little discussion on the nature of the dimethylformamide-induced changes. 
Heydorn and colleagues (1984) found desmethylimipramine- and reserpine-induced 
modulations after the electrophoretic separation of the proteins of discrete regions the 
rat central nervous system. The authors attempted to integrate these findings into 
what is known about noradrenergic neurotransmission, but the study appears to be 
preliminary and the conclusions speculative. It seems, therefore, that there is some 
difficulty in attaching biological significance to data generated by means of two-
dimensional gel electrophoresis, and without the careful establishment of goals the 
generation of such data may become an end in itself. 
Some other studies have utilised two-dimensional gel electrophoresis not in order to 
generate primary data but as a tool to analyze narrowly focussed biological entities. 
For example, Heikkila and co-workers (1981) studied the transient disaggregation of 
polysomes to monosomes in rabbit brain. Lysergic acid diethylamide mediates this 
process in both free and membrane-bound polysomes, and the use of two-
dimensional gel electrophoresis made possible the detection of a 7 4 kd protein 
involved in the disaggregation process. Vlasuk and Walz (1980), in an electrophoretic 
study of liver microsomes, found that phenobarbitone and beta-methylcholanthrene 
induced differences in the synthesis of putative cytochrome P-450 polypeptides. 
Pipkin and co-workers (1985) found that isoproterenol and sodium phenobarbitone 
enhanced the metabolism associated with regeneration in proliferating liver, and two-
dimen~ional gel electrophoresis was used to study protein synthesis during specific 
phases of the liver cell cycle. 
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5.3 Strategies for the Identification of Specific Proteins 
The information on individual proteins derived from the gel viz. molecular weight, iso-
electric point, and relative copy number, is usually insufficient for protein identification. 
Additional identification techniques have to be utilized. 
The most direct way of establishing the identity of a specific protein involves first 
isolating it from the other brain proteins and then obtaining the amino-acid sequence. 
Protein isolation may be achieved by excising the spot from the gel, although the 
percentage recovery is likely to be low, and there is also likely to be a problem with 
contamination (particularly sodium dodecyl sulphate). Nevertheless, interest in 
obtaining a specific polypeptide directly from the gel has recently been revived and 
refinements have been introduced (Kennedy et al, 1988; Eckerskorn et al., 1988). 
An alternative strategy for the isolation of a specific protein involves subjecting the 
source material (homogenized fetal brain) to column chromatography. Two-
dimensional gels may then be run at various stages during the isolation procedure to 
confirm that the correct protein fraction is being enriched (Torres et al., 1985). Since 
there is no restriction on the amount of starting material, a protein present even in low 
concentration may be isolated. Liquid chromatography is being increasingly used in 
the separation and isolation of proteins, and is an alternative to column 
chromatography for the isolation procedure mentioned above (see Hunkapiller et al. , 
1984). Whatever the technology used, the isolation of a protein is a time-consuming 
task that represents a major research commitment. 
The determination of the amino-acid sequence of the purified protein usually requires 
access to specialist protein chemistry facilities, and the use of an automated amino-
acid analyzer, although an alternative is a liquid chromatograph that has been set-up 
specially for the task (Hunkapiller et al., 1984). 
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Once the amino-acid sequence is known, then the identity of the protein may be 
obtainable from a protein "library" (see Eckerskorn ef al., 1988). The identification of a 
murine polypeptide does not necessarily require a murine protein database; there 
appears to be sufficient homology between the proteins of mammalian species, and 
also different cell types, for this not to be essential. For example, Mcconkey (1982) 
was able to show, using two-dimensional gel electrophoresis, that at least half of the 
370 denatured polypeptides from hamster cells and human cells are indistinguishable 
in terms of isoelectric point and molecular weight. 
All the phenytoin-modulated proteins are represented by minor spots, and this makes 
the determination of their amino-acid sequence an essential route to identification. 
Some prominent proteins (eg. actin) may be identified simply from their positions on 
the gels, since they occur in the same positions on gels derived from other tissues. 
Proteins available commercially in pure form may be added to the sample containing 
the protein of interest to test whether or not co-migration occurs. Any information, 
even of a general nature, that is available about the target protein may be utilized to 
speed up the purification and identification process. If it is known, for instance, that 
the unknown protein is a protease, then substrate affinity chromatography may be 
performed for rapid purification. 
Once enough of the unknown protein has been isolated it may be used as an antigen 
to raise antibodies. Radioactive markers conjugated to these antibodies should 
reveal the distribution within the brain of the drug-modulated protein. The intracellular 
locality of the protein may also be determined, and this information may well give 
important hints as to the function of the protein. 
Until the drug-modulated proteins are identified, the data available from the two-
dimensional gels must necessarily be seen as preliminary. However, it cannot simply 
be assumed that the identification of drug-modulated proteins will reveal the 
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fundamental biological events that occur when a teratogen stimulates the modulation of 
those proteins. The observed modulations may be secondary, or even tertiary, 
manifestations, in which case the available data may well be insufficient to allow a 
meaningful assessment to be made of biological responses that occur after drug 
exposure. If a strong relationship can be found between the various drug-modulated 
proteins, either in terms of function, structure, or intracellular position, then it may be 
much easier to hypothesize on the sequence of events that follows from drug exposure. 
5.4 The Conceptual Difficulties of an Holistic Approach 
The interpretational difficulties mentioned in the previous section are more or less 
inherent to an holistic approach. In such an experimental procedure the investigator 
subjects the intact organism to an intervention, and then records the morphological , 
histological or molecular outcome. Although this is a long-established and valuable 
scientific method, it is not without limitations. For one thing, the achievement of positive 
results is more or less fortuitous, and negative results represent a cul-de-sac, leaving no 
alternative approach and giving no hint as to how the problem may be reformulated. 
Moreover, it is often difficult or impossible to grade the various items of data in terms of 
their importance, and unless the findings can be placed in some or other context, the 
investigator may not be able to assign to them value or significance. These comments 
certainly apply to the data on the gels, but they may also apply after the drug-modulated 
proteins have been identified, in which case the task of identification will have been an 
end in itself. 
The alternative is to adopt a reductionistic approach (see Nagel (1971) for general 
comments). Experimentally this involves the selection of a specific biological process 
or entity, which is then studied independently of the organism as a biological 
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approximation of what actually happens. Ideally, the material under study should be 
highly defined and in some situations it is feasible that most, if not all , of the 
components of the entity may be known. Simplicity is the key, since simplicity allows 
the investigator to design experiments in such a way as to obtain unequivocal answers 
to specific questions. A series of carefully designed experiments may reveal a great 
deal about the biological entity under investigation, and this knowledge may then be 
"extrapolated" to more complex levels. As Karl Popper (1981) puts it: " ... whenever 
we can explain entities and events on a higher level by those of a lower level ... we can 
say that we have added much to our understanding of the higher level. As a research 
programme, reductionism is not only important, but it is part of the programme of 
science whose aim is to explain and to understand." 
Clearly the formulation of an experimental protocol that will fulfill some or all of the 
criteria of such a reductionistic approach is crucial. In fact, such a formulation must 
presuppose detailed knowledge of, and extensive familiarity with, the biological entity 
of choice, and the selection of a suitable area of research is therefore in itself a 
significant step to the eventual solution of the problem. It is not clear, however, how 
the present study may be reformulated in terms of a reductionistic approach. In fact 
two-dimensional gel electrophoresis may be used more productively in an analytical 
capacity, rather than as a means of generating primary data. In the following section 
some tentative comments will be offered on how reductionistic principles may be 
utilised to investigate protein modulations in the fetal brain, within the context of 
teratology. 
In teratological research an holistic approach has long been favoured. This is partly 
due to the clinical contribution expected of teratological research e.g. strategies for the 
prediction of the teratogenic potential of new drugs, and screening procedures for 
assigning relative teratogenic risk to drugs currently in use (see for example Schmid, 
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1987). While such endeavours are essential, the strategies used to address these 
issues are not wholly appropriate to answer mechanistic questions, or to solve 
complex biological problems. Many of the advances in modern biochemistry and 
molecular biology have come as a result of the acceptance that vital processes may 
be removed from their normal contexts and reassembled in vitro in a form where they 
retain a specific and limited function, and where simple manipulations may provide 
YES/NO answers. Even if initially the information obtained may appear fragmentary 
and inconsequential, the data will be precise enough to lead to the formulation of 
other, more wide-ranging, objectives. Such a strategy may provide insight into 
fundamental and important teratological processes, and at the same time greatly assist 
in the search for effective screening procedures. 
5.5 Research ideas for the study of drug-modulated fetal proteins 
An examination of the heat-shock response within the framework of a teratological 
investigation may be extremely rewarding. The induction of these proteins may in fact 
occur in fetal mouse brain during mid- and late-gestation, and if so, then it would be 
interesting to know how different drugs affect the level and the kinetics of expression. 
It would also be interesting to confirm whether the fetal mouse brain expresses the 
heat-shock proteins constitutively (see for example Barnier et al., 1987), and whether 
this expression differs between fetal and adult brain. If the fetal heat-shock proteins 
are inducible, then the effects of disulfiram and phenytoin may be analysed and 
compared. The level of expression of the heat-shock proteins may conceivably be 
used as a measure of the stress that drugs exert on the fetus, and this may constitute 
the basis of a teratogen screening procedure. 
The protective function that has been attributed to the heat-shock response is 
potentially of the highest relevance to the study of drug-induced injury to the fetus. 
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Only one literature report has, to my knowledge, mentioned this protective capacity of 
the heat-shock response within the context of teratology. Buzin and Bournias-
Vardiabasis (1982) were able to show that mild heat pretreatment of Drosophila 
embryonic cells protects them from exposure to teratogens (coumarin and phenytoin). 
It may therefore be fruitful to explore the protective role of heat-shock inducers in the 
fetal mammalian brain. For example, will the prior administration of a non-teratogenic 
dosage of disulfiram, followed by a teratogenic dosage of phenytoin, prevent the 
manifestations of phenytoin teratogenicity? Will the protein modulations that follow 
phenytoin administration (as detected in the present study) be suppressed by the prior 
administration of disulfiram? Answers to these questions may reveal a great deal 
about the kinetics of unscheduled protein synthesis in response to drug exposure. 
The ability to elicit a protective response in the fetus (if it exists) may be useful 
therapeutically, for example, in cases of high fever during critical stages of pregnancy. 
The administration of a sub-teratogenic dosage of a drug, that induces the heat-shock 
response, immediately after the accidental or deliberate ingestion of large amounts of 
phenytoin (or any other teratogen), may provide the fetus with a measure of 
protection. 
As in the case of the heat-shock proteins, ornithine decarboxylase expression appears 
to be sensitive to diverse environmental factors. Pegg and Mccann (1982) have 
reported that ornithine decarboxylase activity may be increased many-fold within a few 
hours of exposure to environmental stimuli, including drugs. Dienel and Cruz (1984) 
were able to show that ornithine decarboxylase activity in the rat brain increased two-
to sixfold after different modes of injury, including mechanical and thermal injury, and 
also in response to exposure to neurotoxins. 
Ornithine decarboxylase does not appear to belong to the family of heat-shock 
proteins, although it too may be useful as an indicator of stressful or noxious stimuli 
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(Slotkin et al. , 1985). The likelihood exists that it is inducible by toxic or potentially 
teratogenic dosages of disulfiram and phenytoin. However, it is unlikely that ornithine 
decarboxylase will be detectable on gels, because Dienel and Cruz (1984) reported 
that the enzyme represents only about 1 o-6 per cent of the protein in a 17 OOOg brain 
supernatant. Whether or not the enzyme is in fact modulated by phenytoin and 
disulfiram, and the extent of the modulation, may be determined from an enzyme 
activity assay. 
The importance of ornithine decarboxylase in a teratological context lies in the fact that 
it is the rate-limiting enzyme in the biosynthesis of the polyamines spermine and 
spermidine. These are percusors of macromolecular biosynthesis, and are known 
to play an essential role in many aspects of normal cellular growth and differentiation 
(Pegg and Mccann, 1982). Ornithine decarboxylase is very active in the fetus and its 
expression in the mouse fetus fluctuates during gestation, reaching maximum activity 
on gestational day 8 (O'Toole et al., 1989). The enzyme, however, appears to 
participate only in discrete developmental events, since inhibition studies have shown 
that not all growth processes are highly dependent on elevated ornithine 
decarboxylase activity (Slotkin et al., 1984). 
Pharmacologically active substances therefore appear potentially to have a wide 
spectrum of effects on fetal tissues. Some of these substances have been shown to 
induce the unscheduled synthesis of proteins, although as yet little is known about 
what effects drug-induced protein synthesis may have on the highly ordered and 
sensitive processes of development. From a reductionistic viewpoint, it seems 
possible to utilize selected drugs as tools in order to manipulate specific molecular 
processes within the fetus, and thereby to improve our understanding of fetal 
vulnerability to xenobiotics, and to shed light on the developmental process itself. 
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1 ,6% pH range 5-7, and 0,4% pH range 3-10) , and 5% 2-
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